

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3,	
		AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 08:54:45 ON 18 FEB 2009

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 08:55:08 ON 18 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 FEB 2009 HIGHEST RN 1107694-62-1  
DICTIONARY FILE UPDATES: 17 FEB 2009 HIGHEST RN 1107694-62-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10577698.str



chain nodes :  
7 8 11 12 13 14 15 16  
ring nodes :  
1 2 3 4 5 6  
chain bonds :  
5-7 7-8 8-11 11-12 11-13 14-15 15-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
exact/norm bonds :  
7-8 8-11 11-12 11-13 14-15  
exact bonds :  
5-7 15-16  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 11:CLASS  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 19:Atom

L1            STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1            STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:55:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 342350 TO ITERATE

0.6% PROCESSED            2000 ITERATIONS            5 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE   \*\*INCOMPLETE\*\*  
                              BATCH   \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS:        6813064 TO 6880936  
PROJECTED ANSWERS:            15362 TO    18872

L2            5 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 08:55:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6842174 TO ITERATE

5.8% PROCESSED	393593 ITERATIONS	207 ANSWERS
9.6% PROCESSED	657228 ITERATIONS	451 ANSWERS
12.2% PROCESSED	831393 ITERATIONS	522 ANSWERS
13.6% PROCESSED	933903 ITERATIONS	619 ANSWERS
14.0% PROCESSED	955643 ITERATIONS	619 ANSWERS
14.4% PROCESSED	982795 ITERATIONS	621 ANSWERS
14.4% PROCESSED	982795 ITERATIONS	621 ANSWERS
14.5% PROCESSED	995082 ITERATIONS ( 1 INCOMPLETE)	622 ANSWERS
14.5% PROCESSED	995082 ITERATIONS ( 1 INCOMPLETE)	622 ANSWERS
14.5% PROCESSED	995082 ITERATIONS ( 1 INCOMPLETE)	622 ANSWERS

14.5% PROCESSED 995082 ITERATIONS ( 1 INCOMPLETE) 622 ANSWERS  
 14.5% PROCESSED 995082 ITERATIONS ( 1 INCOMPLETE) 622 ANSWERS  
 14.5% PROCESSED 995082 ITERATIONS ( 1 INCOMPLETE) 622 ANSWERS

---Logging off of STN---

14.5% PROCESSED 995082 ITERATIONS ( 1 INCOMPLETE) 622 ANSWERS  
 END

Unable to generate the STN prompt.  
 Exiting the script...

```
=> fil reg
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                5.76          5.98
```

FILE 'REGISTRY' ENTERED AT 09:02:06 ON 18 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 17 FEB 2009 HIGHEST RN 1107694-62-1  
 DICTIONARY FILE UPDATES: 17 FEB 2009 HIGHEST RN 1107694-62-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>  
 Uploading C:\Program Files\STNEXP\Queries\10577698narrower.str



chain nodes :  
 7 8 11 12 13 14 15

```

ring nodes :
1  2  3  4  5  6  16  21  22  23  24  25  26  27  28  29
chain bonds :
5-7  7-8  8-11  11-12  11-13  14-15  15-16
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-21  16-25  21-22  22-23  23-24  23-26  24-25
24-29  26-27  27-28  28-29
exact/norm bonds :
7-8  8-11  11-12  11-13  14-15  16-21  16-25  21-22  22-23  23-24  23-26  24-25
24-29  26-27  27-28  28-29
exact bonds :
5-7  15-16
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 16 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 19:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom


```

L4 STRUCTURE UPLOADED

```

=> d 14
L4 HAS NO ANSWERS
L4 STR

```



Structure attributes must be viewed using STN Express query preparation.

```

=> s 14
SAMPLE SEARCH INITIATED 09:04:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 19822 TO ITERATE

10.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 388009 TO 404871

```

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 09:04:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 398372 TO ITERATE

100.0% PROCESSED 398372 ITERATIONS

173 ANSWERS

SEARCH TIME: 00.00.07


L6 173 SEA SSS FUL L4

=> d scan

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 2-Propenoic acid, 3-[4-[[1-(2-naphthalenyl)ethyl]amino]-3-nitrophenyl]-

MF C21 H18 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40\

'40\' IS NOT VALID HERE


To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN INDEX NAME NOT YET ASSIGNED

MF C21 H21 N O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzenepropanoic acid,  $\alpha$ -methoxy- $\alpha$ -methyl-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl)methyl]amino]-, ethyl ester, ( $\alpha$ S)-


MF C25 H29 N O6 S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[4-[[[(5,6,7,8-tetrahydro-2-naphthalenyl)carbonyl]amino]phenyl]-, ethyl ester  
 MF C22 H23 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN L-Phenylalanine, N-[[[(5S)-6,7-dihydro-3-(phenylmethyl)-5H-pyrrolo[2,1-c]-1,2,4-triazol-5-yl]carbonyl]-4-[(2-naphthalenylcarbonyl)amino]-, methyl ester  
 MF C34 H31 N5 O4

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepentanoic acid,  $\alpha,\alpha$ -difluoro-4-[[5,6,7,8-tetrahydro-  
 5,5,8,8-tetramethyl-2-naphthalenyl]carbonylamino]-, ethyl ester  
 MF C25 H29 F2 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepentanoic acid,  $\alpha$ -ethoxy-4-[[6-[(methylsulfonyl)oxy]-2-  
 naphthalenyl]methyl]amino]-  
 MF C25 H29 N O6 S  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid,  $\alpha$ -methoxy-4-[[6-[(methylsulfonyl)oxy]-2-  
 naphthalenyl]methyl]amino]-, ethyl ester, ( $\alpha$ S)-  
 MF C24 H27 N O6 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenebutanoic acid, 3-[[[4-(dimethylamino)-3-(trifluoromethyl)phenyl]sulfonyl](2-naphthalenylmethyl)amino]-gamma-oxo-alpha-(phenylmethyl)-, methyl ester  
 MF C38 H35 F3 N2 O5 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenecetic acid, 2-[[[4-(dimethylamino)-3-(trifluoromethyl)phenyl]sulfonyl](1,3-difluoro-2-naphthalenyl)amino]-5-methyl-  
 MF C19 H15 F2 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid, 5-chloro-2-[(1-chloro-3-fluoro-2-naphthalenyl)amino]-  
 MF C18 H12 Cl2 F N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid, 5-chloro-2-[(1,3-dichloro-2-naphthalenyl)amino]-  
 MF C18 H12 Cl3 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid, 5-methyl-2-(2-naphthalenylamino)-  
 MF C19 H17 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[3-[[[(8-methoxy-2,2-dimethyl-2H-1-benzopyran-7-yl)methyl](2-naphthalenylicarbonyl)amino]phenyl]-, methyl ester  
 MF C34 H31 N O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenebutanoic acid,  $\gamma$ -(hydroxyimino)-4-[(2-naphthalenylcarbonyl)amino]-  
 MF C21 H18 N2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid, 4,4'-[[1,1'-biphenyl]-4,4'-diylbis(2-naphthalenyylimino)]bis-, dimethyl ester, polymer with 1,2-ethanediol (9CI)  
 MF (C52 H44 N2 O4 . C2 H6 O2)x  
 CI PMS


\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\*

CM 1






L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid, 3-[(2-naphthalenylcarbonyl)amino]-  
 MF C19 H15 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Phenylalanine, N-(aminoiminomethyl)-4-[[[(2S)-2-[(aminoiminomethyl)amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI)  
 MF C24 H27 N7 O3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[3-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]phenyl]-  
 MF C24 H27 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenecetic acid, 4-[[[(2S)-2-[[[trans-4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]cyclohexyl]carbonyl]amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]-, phenylmethyl ester  
 MF C41 H47 N3 O6

Absolute stereochemistry. Rotation (+).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenebutanoic acid, 4-[[[6-(2-quinolinylmethoxy)-2-naphthalenyl]carbonyl]amino]-, methyl ester  
 MF C32 H28 N2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenebutanoic acid, 4-[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]-  
 MF C33 H30 N2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenesacetic acid, 4-[[2-(2-naphthalenyl)ethyl]amino]- $\alpha$ -oxo-  
 MF C20 H17 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid, 5-[[[1-hydroxy-2-naphthalenyl]carbonyl]amino]-2-(methyltetradecylamino)-  
 MF C35 H48 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 2-bromo-3-[2-[(methoxycarbonyl)(2-naphthalenylmethyl)amino]phenyl]-, ethyl ester, (2Z)-  
 MF C24 H22 Br N O4

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenecetic acid, 4-[[[(3-ethoxy-2-naphthalenyl)carbonyl]amino]-  
 MF C21 H19 N O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[4-[[[(6-methoxy-2-naphthalenyl)carbonyl]amino]phenyl]-  
 MF C21 H17 N O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid, 4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]-  
 MF C24 H29 N O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenepropanoic acid, 4-[(2-naphthalenylmethyl)amino]-  
 MF C20 H19 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[2-[(2-naphthalenylcarbonyl)amino]phenyl]-  
 MF C20 H15 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN L-Arginine, mono[α-ethoxy-4-[[[1,2,3,4-tetrahydro-6-  
 [(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]benzenepropanoate] (9CI)  
 MF C23 H29 N O6 S . C6 H14 N4 O2

CM 1




CM 2

Absolute stereochemistry.



L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzenepropanoic acid,  $\alpha$ -methoxy-4-[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]-, ( $\alpha$ S)-  
MF C22 H23 N O6 S  
CI COM

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN Benzenepropanoic acid, 4,4'-[2,6-naphthalenediylbis(phenylimino)]bis-, dimethyl ester, polymer with 1,2-ethanediol (9CI)  
MF (C42 H38 N2 O4 . C2 H6 O2)x  
CI PMS

\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\*


CM 1



CM 2




L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenebutanoic acid, 3-[(2-anthracenylsulfonyl)(2-naphthalenylmethyl)amino]-γ-oxo-α-(phenylmethyl)-  
 MF C42 H33 N O5 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenesacetic acid, 5-chloro-2-[(3-chloro-1-fluoro-2-naphthalenyl)amino]-  
 MF C18 H12 Cl2 F N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzenesacetic acid, 2-[(1-fluoro-2-naphthalenyl)amino]-5-methyl-  
 MF C19 H16 F N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzeneacetic acid, 5-chloro-2-[(1-chloro-6-fluoro-2-naphthalenyl)amino]-  
 MF C18 H12 Cl2 F N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN Benzeneacetic acid, 5-chloro-2-[(1-chloro-2-naphthalenyl)amino]-  
 MF C18 H13 Cl2 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)-2-naphthalenylamino]phenyl]-,  
 methyl ester  
 MF C27 H27 N O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
 IN 2-Propenoic acid, 3-[3-[(2-naphthalenylcarbonyl)amino]phenyl]-  
 MF C20 H15 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L6 173 ANSWERS REGISTRY COPYRIGHT 2009 ACS ON STN  
 IN 2-Propenoic acid, 3-[4-[(2-naphthalenylcarbonyl)amino]phenyl]-  
 MF C20 H15 N O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	187.80	193.78

FILE 'CAPLUS' ENTERED AT 09:05:00 ON 18 FEB 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Feb 2009 VOL 150 ISS 8  
 FILE LAST UPDATED: 17 Feb 2009 (20090217/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 08:54:45 ON 18 FEB 2009)

FILE 'REGISTRY' ENTERED AT 08:55:08 ON 18 FEB 2009

L1 STRUCTURE UPLOADED  
L2 5 S L1  
L3 QUE L1

FILE 'REGISTRY' ENTERED AT 09:02:06 ON 18 FEB 2009

L4 STRUCTURE UPLOADED  
L5 0 S L4  
L6 173 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:05:00 ON 18 FEB 2009

=> s l6  
L7 57 L6

=> s l6 and (pry<2004)  
57 L6  
4266863 PRY<2004  
L8 36 L6 AND (PRY<2004)

=> s 1-36 ibib abs hitstr  
10014452 1  
364260 36  
16 IBIB  
249334 ABS  
4 ABSES  
249338 ABS  
(ABS OR ABSES)  
L9 0 1-36 IBIB ABS HITSTR  
(1(W)36(W)IBIB(W)ABS(W)HITSTR)

=> s l8  
57 L6  
4266863 PRY<2004  
L10 36 L6 AND (PRY<2004)

=> d 1-36 ibib abs hitstr

L10 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2005:516308 CAPLUS

DOCUMENT NUMBER: 143:43695

TITLE: Preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase (HDAC) inhibitors.

INVENTOR(S): Leblond, Bertrand; Beausoleil, Eric

PATENT ASSIGNEE(S): Exonhit Therapeutics S.A., Fr.

SOURCE: Eur. Pat. Appl., 50 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 1541549	A1	20050615	EP 2003-293143	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

WO 2005058803 A1 20050630 WO 2004-IB4334 20041210 <--  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
EP 1692097 A1 20060823 EP 2004-806498 20041210 <--  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS  
US 20070129368 A1 20070607 US 2006-581947 20060606 <--  
PRIORITY APPLN. INFO.: EP 2003-293143 A 20031212 <--  
WO 2004-IB4334 W 20041210  
OTHER SOURCE(S): CASREACT 143:43695; MARPAT 143:43695  
GI



AB Title compds. [I; R = CONR7R8, COCONR8R9, COCONHMe, COCF3, etc.; R7 = OH, OR9, 2-aminophenyl; R8, R9 = H, alkyl; X1 = C, O, N, S; R1, R2 = null, H, alkyl, 1-2 O; X2, X3 = CH, O, N; X2X3 = S, O, N; X4 = N, CH; R3-R5 = H, OH, NH2, halo, alkyl, perfluoroalkyl, etc.; L = alkylene, alkenylene, alkynylene, (aromatic) cycloalkyl, O, CO, CONH, CF2CONH, SO2NH, NMeSO2, etc.], were prepared Thus, 4-[2,2-difluoro-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetylamino]benzoic acid (preparation given) was stirred with SOC12 and cat. DMF at 0° for 1 h. The residue in CH2Cl2 was added to a mixture prepared from hydroxylamine hydrochloride, H2O, and Et3N in THF at 0° followed by stirring at 0° for 10 min. and at room temperature for 17.75 h to give 33.4% 4-[2,2-difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido]-N-hydroxybenzamide (EHT 9299). The latter showed HDAC inhibitory activity with IC50 = 424 nM.  
IT 853728-69-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)  
RN 853728-69-5 CAPLUS  
CN Benzenecetic acid,  $\alpha$ , $\alpha$ -difluoro-4-[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbonylamino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:395259 CAPLUS

DOCUMENT NUMBER: 142:446998

TITLE: Preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase

INVENTOR(S): Debnath, Bhuniya; Gurram, Ranga Madhavan; Das Saibal, Kumar; Javed, Iqbal; Ranjan, Chakrabarti; Labanyamoy, Kole

PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040102	A2	20050506	WO 2004-IB3429	20041020 <--
WO 2005040102	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1680397	A2	20060719	EP 2004-769681	20041020 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070093476	A1	20070426	US 2006-577698	20060428 <--
PRIORITY APPLN. INFO.: IN 2003-CH862 A 20031028 <-- WO 2004-IB3429 W 20041020				
OTHER SOURCE(S): CASREACT 142:446998; MARPAT 142:446998				

GI



AB Title compds. I [Ar = mono- or polycyclic aromatic or partially saturated aromatic

polycycle optionally containing up to 3 heteroatoms selected from N, S, or O; m and n independently = 0-6; A = bond, O, S; Y = (CH<sub>2</sub>)p, (CH<sub>2</sub>)pB(CH<sub>2</sub>)q, (CH<sub>2</sub>)xB(CH<sub>2</sub>)pD(CH<sub>2</sub>)q; p, q, and x independently = 0-6; B and D independently = S, O, bond, etc.; R<sub>1</sub> and R<sub>2</sub> independently = H, alkyl, alkoxy, etc.; R<sub>1</sub> and R<sub>2</sub> together may form 3-8 membered cyclic ring optionally containing 1-2 heteroatoms selected from O, S, or N; R<sub>3</sub> = H, (un)substituted alkyl, cycloalkyl, etc.; with provision] and their pharmaceutically acceptable salts, are prepared and disclosed as useful PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase. Thus, e.g., II was prepared by mesylating 6-hydroxy  $\beta$ -naphthoate followed by reduction of the Me ester and subsequent oxidation to the resp. aldehyde, which was then utilized in a reductive amination employing (S)-Et 2-methoxy-3-(4-aminophenyl)propionate (preparation given). The ability of I to lower triglyceride levels in swiss albino mice was evaluated and selected compds. of the invention revealed redns. in the range of 10-79%. I as agonists of PPAR- $\alpha$  and PPAR- $\gamma$  and inhibitors of HMG CoA reductase should prove useful in the treatment of diabetes and dyslipidemia. Pharmaceutical composition comprising I is disclosed.

IT 851122-20-8P 851122-21-9P 851122-22-0P  
851122-31-1P 851122-32-2P 851122-42-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)

RN 851122-20-8 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -methoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]-, ethyl ester, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 851122-21-9 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]-, ethyl ester (CA INDEX NAME)




RN 851122-22-0 CAPLUS

CN Benzenepentanoic acid, α-ethoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]-, ethyl ester (CA INDEX NAME)




RN 851122-31-1 CAPLUS

CN Benzenepentanoic acid, α-ethoxy-4-[[[1,2,3,4-tetrahydro-6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]-, ethyl ester (CA INDEX NAME)



RN 851122-32-2 CAPLUS


CN Benzenepropanoic acid, α-ethoxy-4-[[[3-[1,2,3,4-tetrahydro-6-[(methylsulfonyl)oxy]-2-naphthalenyl]propyl]amino]-, ethyl ester (CA INDEX NAME)



RN 851122-42-4 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -methoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 851122-43-5P 851122-44-6P 851122-53-7P

851122-54-8P 851122-64-0P 851122-66-2P


851122-78-6P 851122-81-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenoxyalkanoates as PPAR- $\alpha$  and PPAR- $\gamma$  agonists and inhibitors of HMG CoA reductase)


RN 851122-43-5 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]- (CA INDEX NAME)




RN 851122-44-6 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]- (CA INDEX NAME)




RN 851122-53-7 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[[[1,2,3,4-tetrahydro-6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]- (CA INDEX NAME)



RN 851122-54-8 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -ethoxy-4-[[3-[[1,2,3,4-tetrahydro-6-(methylsulfonyl)oxy]-2-naphthalenyl]propyl]amino]- (CA INDEX NAME)



RN 851122-64-0 CAPLUS


CN L-Arginine, mono[( $\alpha$ S)- $\alpha$ -methoxy-4-[[[6-[(methylsulfonyl)oxy]-2-naphthalenyl]methyl]amino]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 851122-42-4

CMF C22 H23 N O6 S

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 851122-66-2 CAPLUS


CN L-Arginine,  $\alpha$ -ethoxy-4-[[[6-[(methylsulfonyl)oxy]-2-

naphthalenyl)methyl]amino]benzenepentanoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 851122-44-6

CMF C25 H29 N O6 S




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.




RN 851122-78-6 CAPLUS

CN L-Arginine, mono[α-ethoxy-4-[[[1,2,3,4-tetrahydro-6-[(methanesulfonyl)oxy]-2-naphthalenyl]methyl]amino]benzenepropanoate] (9CI)  
(CA INDEX NAME)

CM 1

CRN 851122-53-7

CMF C23 H29 N O6 S




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2


Absolute stereochemistry.



RN 851122-81-1 CAPLUS  
 CN L-Arginine, mono[α-ethoxy-4-[[3-[1,2,3,4-tetrahydro-6-  
 [(methylsulfonyl)oxy]-2-naphthalenyl]propyl]amino]benzenepropanoate] (9CI)  
 (CA INDEX NAME)

CM 1


CRN 851122-54-8  
 CMF C25 H33 N O6 S



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:122836 CAPLUS  
 DOCUMENT NUMBER: 142:198983  
 TITLE: Diamine compound polymer having condensed aromatic  
 group and method for its preparation  
 INVENTOR(S): Seki, Mieko; Yoneyama, Hirohito; Okuda, Daisuke;  
 Hirose, Hidekazu; Ozaki, Tadayoshi; Agata, Takeshi;  
 Ishii, Toru; Moriyama, Hiroaki; Mashimo, Kiyokazu;  
 Sato, Katsuhiro  
 PATENT ASSIGNEE(S): Fuji Xerox Co., Ltd., Japan  
 SOURCE: U.S. Pat. Appl. Publ., 34 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050033011	A1	20050210	US 2004-783774	20040220 <--
US 7060783	B2	20060613		
JP 2005053958	A	20050303	JP 2003-205919	20030805
PRIORITY APPLN. INFO.:			JP 2003-205919	A 20030805 <--

GI



AB The d polymer has a condensed aromatic group represented by the following formulas  $H(OY)mO[C(O)AC(O)(YO)m]pH$  and  $B[C(O)AC(O)(YO)mC(O)ZC(O)O(YO)m]pC(O)AC(O)B'$  wherein A represents a structure represented by the following formula I; Y and Z represent hydrocarbylene groups; B and B' each independently represents a group represented by  $-O(YO)mH$  or  $-O(YO)mCOZCOOR'$ , wherein R' is a H atom, an aralkyl group, an aryl group, or an aralkyl group; m represents an integer from 1 to 5; and p represents an integer from 5 to 5000; Ar represents a monovalent aromatic group; X represents a divalent condensed aromatic group; T represents a C1-6 linear hydrocarbylene group or a C2-10 branched hydrocarbylene group; k and n each represents an integer of 0 or 1. The polymer is useful for charge transport materials. Thus, heating a mixture of N-phenyl-N-[4-(2-methoxycarbonylethyl)phenyl]amine 10.0, 1,4-dibromonaphthalene 5.1, K carbonate 6.2 and Cu sulfate pentahydrate 0.5 g in 20 mL n-tridecane at 230° for 33 h gave N,N'-diphenyl-N,N'-bis[4-(2-methoxycarbonylethyl)phenyl]naphthyl-1,4-diamine (II) having m.p. 139-141°. Polymerizing II 1.0 with ethylene glycol 3.0 in the presence of tetrabutoxytitanium 0.04 g at 200° for 3 h and heating at 230° for 4 h while removing excess ethylene glycol at 0.5 mm-Hg gave a polymer.

IT 838896-36-9P 838896-37-0P

RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)  
(manufacture and use of diamine compound polymer having condensed aromatic group)


RN 838896-36-9 CAPLUS

CN Benzenepropanoic acid, 4,4'-[2,6-naphthalenediylbis(phenylimino)]bis-, dimethyl ester, polymer with 1,2-ethanediol (9CI) (CA INDEX NAME)

CM 1

CRN 838896-29-0

CMF C42 H38 N2 O4



CM 2


CRN 107-21-1  
CMF C2 H6 O2




RN 838896-37-0 CAPLUS

CN Poly[oxy-1,2-ethanediyl oxy(1-oxo-1,3-propanediyl)-1,4-phenylene(phenylimino)-2,6-naphthalenediyl(phenylimino)-1,4-phenylene(3-oxo-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 838896-29-0P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(manufacture and use of diamine compound polymer having condensed aromatic group)

RN 838896-29-0 CAPLUS

CN Benzenepropanoic acid, 4,4'-[2,6-naphthalenediylbis(phenylimino)]bis-, dimethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:902361 CAPLUS  
 DOCUMENT NUMBER: 141:395802  
 TITLE: Preparation of substituted phenylalkanoic acids, including amino acid derivatives  
 INVENTOR(S): Van Zandt, Michael C.; Fang, Haiquan; Hu, Shaojing; Whitehouse, Darren  
 PATENT ASSIGNEE(S): The Institutes for Pharmaceutical Discovery, LLC, USA  
 SOURCE: PCT Int. Appl., 131 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092146	A2	20041028	WO 2004-US11650	20040414 <--
WO 2004092146	A3	20041229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004231106	A1	20041028	AU 2004-231106	20040414 <--
CA 2522080	A1	20041028	CA 2004-2522080	20040414 <--
US 20040248937	A1	20041209	US 2004-824057	20040414 <--
EP 1633354	A2	20060315	EP 2004-750170	20040414 <--
EP 1633354	B1	20080123		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004009447	A	20060418	BR 2004-9447	20040414 <--
CN 1794989	A	20060628	CN 2004-80014576	20040414 <--
JP 2006524248	T	20061026	JP 2006-510073	20040414 <--
AT 384526	T	20080215	AT 2004-750170	20040414 <--
NO 2005004769	A	20060103	NO 2005-4769	20051017 <--
IN 2005KN02090	A	20061117	IN 2005-KN2090	20051024 <--
PRIORITY APPLN. INFO.:			US 2003-463102P	P 20030414 <--
			WO 2004-US11650	W 20040414

OTHER SOURCE(S): MARPAT 141:395802  
 GI




I

AB The invention relates to compds. I [n is 0-3; R1 is H, alkyl, phenylalkyl or alkenyl; R2 is Ph, phenylalkyl, alkyl, carbamoylalkyl, alkylsulfonylalkyl, heterocycloalkyl, etc.; R3 is H or CO2R1; R20-R23 are independently H, arylalkoxy, arylalkyl, halo, alkyl, OH, alkoxy, NO2, NH2, alkylamino, etc.; L is SO2NH, sulfonyl(alkylimino), NHSO2, O, CONH, carbonyl(alkylimino), SO2, carbonylalkylene, alkylenecarbonyl, NH or alkylimino (the alkyl group are optionally substituted with Ph or substituted phenyl); L2 is a bond, CONR9, NR9CO, alkylene-CONR9, NR9, etc. (R9 is H or alkyl optionally substituted with CO2H, arylsulfonyl or arylalkyl); ring A is (un)substituted Ph, naphthyl, thiazolyl, pyrazolyl, furanyl, dihydropyrazolyl, benzofuranyl, dibenzofuranyl, pyrimidyl, pyridyl, quinolinyl, naphthyl, quinazolinyl, benzo[b]thiophene, imidazolyl, isothiazolyl, pyrrolyl, oxazolyl or triazolyl; Q is H, aryl, arylcarbonylaryl, alkyl, halo, etc.; L3 is a bond, alkyleneoxy, oxyalkylene, alkylene, alkenylene or CO; Z is absent, H, aroylamino, (un)substituted Ph or cycloalkylcycloalkanoyl(alkyl)amino] and their pharmaceutically-acceptable salts, which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compds. include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases such as cancer and neurodegenerative diseases. Thus, 2-[4-[4-(4-chlorophenyl)-5-(4-ethylphenyl)thiazol-2-ylcarbamoyl]benzenesulfonylamino]-3-phenylpropionic acid was prepared by cyclocondensation of 4-ClC6H4COCH2C6H4Et-4 (preparation given) with thiourea, acylation with 4-ClSO2C6H4CO2H, and coupling with phenylalanine tert-Bu ester hydrochloride. The product was shown to increase the glucose infusion rate in rats at 30 mg/kg.

IT 782484-12-2P 782484-37-1P 782484-38-2P  
782484-39-3P 782484-40-6P 782484-42-8P  
782484-60-0P 782484-67-7P 782484-68-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of substituted phenylalkanoic acids, including amino acid derivs., for treatment of diabetes)


RN 782484-12-2 CAPLUS

CN Benzenebutanoic acid, 3-[(2-naphthalenylmethyl)[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-γ-oxo-α-(phenylmethyl)- (CA INDEX NAME)




RN 782484-37-1 CAPLUS

CN Benzenebutanoic acid, 3-[(2-naphthalenylmethyl)(2-naphthalenylsulfonyl)amino]- $\gamma$ -oxo- $\alpha$ -(phenylmethyl)-, methyl ester (CA INDEX NAME)




RN 782484-38-2 CAPLUS

CN Benzenebutanoic acid, 3-[(2-naphthalenylmethyl)(2-naphthalenylsulfonyl)amino]- $\gamma$ -oxo- $\alpha$ -(phenylmethyl)- (CA INDEX NAME)




RN 782484-39-3 CAPLUS

CN Benzenebutanoic acid, 3-[(2-anthracenylsulfonyl)(2-naphthalenylmethyl)amino]- $\gamma$ -oxo- $\alpha$ -(phenylmethyl)- (CA INDEX NAME)




RN 782484-40-6 CAPLUS

CN Benzenebutanoic acid, 3-[[[4-(dimethylamino)-3-fluorophenyl]sulfonyl](2-naphthalenylmethyl)amino]- $\gamma$ -oxo- $\alpha$ -(phenylmethyl)-, methyl ester (CA INDEX NAME)




RN 782484-42-8 CAPLUS

CN Benzenebutanoic acid, 3-[[[4-(dimethylamino)-3-(trifluoromethyl)phenyl]sulfonyl](2-naphthalenylmethyl)amino]-gamma-oxo-alpha-(phenylmethyl)-, methyl ester (CA INDEX NAME)




RN 782484-60-0 CAPLUS

CN Benzenebutanoic acid, 3-[[[3,4-dichlorophenyl]sulfonyl](2-naphthalenylmethyl)amino]-gamma-oxo-alpha-(phenylmethyl)-, methyl ester (CA INDEX NAME)




RN 782484-67-7 CAPLUS

CN Benzenebutanoic acid, 3-[[[4-methoxy-3-(trifluoromethyl)phenyl]sulfonyl](2-naphthalenylmethyl)amino]-gamma-oxo-alpha-(phenylmethyl)- (CA INDEX NAME)



RN 782484-68-8 CAPLUS

CN Benzenebutanoic acid, 3-[[[(3,4-difluorophenyl)sulfonyl](2-naphthalenylmethyl)amino]-gamma-oxo-alpha-(phenylmethyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2004:467845 CAPLUS

DOCUMENT NUMBER: 141:38434

TITLE: Preparation of substituted amino phenylacetic acids and derivatives and their use as cyclooxygenase-2 (COX-2) inhibitors

INVENTOR(S): Fujimoto, Roger Aki; McQuire, Leslie Wighton; Monovich, Lauren G.; Mugrage, Benjamin Biro; Parker, David Thomas; Van Duzer, John Henry; Wattanasin, Sompong

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048314	A1	20040610	WO 2003-EP13246	20031125 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT,				


LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
 RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN,  
 YU, ZA, ZW  
 RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,  
 DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
 SI, SK, TR  
 CA 2507458 A1 20040610 CA 2003-2507458 20031125 <--  
 AU 2003292112 A1 20040618 AU 2003-292112 20031125 <--  
 US 20040132769 A1 20040708 US 2003-724457 20031125 <--  
 US 7202364 B2 20070410  
 EP 1567477 A1 20050831 EP 2003-767652 20031125 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003016615 A 20051011 BR 2003-16615 20031125 <--  
 CN 1729157 A 20060201 CN 2003-80107251 20031125 <--  
 JP 2006507336 T 20060302 JP 2004-554464 20031125 <--  
 PRIORITY APPLN. INFO.: US 2002-429222P P 20021126 <--  
 WO 2003-EP13246 W 20031125 <--  
 OTHER SOURCE(S): MARPAT 141:38434  
 GI




AB The title compds. I (R = H, alkyl, cycloalkyl, halo, alkoxy, F3CO, Me3C, cyano, R1 = biaryl,  $\beta$ -naphthyl derivative, bicyclic heterocyclic aryl, cycloalkyl monocyclic carbocyclic aryl, cycloalkane fused-monocyclic carbocyclic aryl) were prepared Thus,  
 N,N-dimethyl-2-(2',3',5',6'-tetrafluoro-4'-phenylanilino)phenylacetamide was hydrolyzed to give I (R = H, R1 = 4-PhC6F4).  
 IT 702641-15-4P 702641-16-5P 702641-17-6P  
 702641-18-7P 702641-25-6P 702641-26-7P  
 702641-46-1P 702641-47-2P 702641-57-4P  
 702642-75-9P 702642-76-0P 702642-78-2P  
 702642-80-6P 702642-82-8P 702642-84-0P  
 702642-86-2P 702642-88-4P 702642-90-8P  
 702642-93-1P 702642-95-3P 702643-07-0P  
 702643-09-2P 702643-38-7P 702643-40-1P  
 702643-43-4P 702643-45-6P 702643-46-7P  
 702643-47-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of (aminophenyl)acetic acid derivs. and their cyclooxygenase-2 inhibitory activity for treating rheumatoid arthritis, osteoarthritis, pain, dysmenorrhea, neoplasms, and inflammation)  
 RN 702641-15-4 CAPLUS  
 CN Benzeneacetic acid, 2-[(1-chloro-2-naphthalenyl)amino]- (CA INDEX NAME)




RN 702641-16-5 CAPLUS  
 CN Benzenesulfonamide, 2-[(1-chloro-2-naphthalenyl)amino]-5-methyl- (CA INDEX NAME)




RN 702641-17-6 CAPLUS  
 CN Benzenesulfonamide, 5-chloro-2-[(2-naphthalenylamino)- (CA INDEX NAME)




RN 702641-18-7 CAPLUS  
 CN Benzenesulfonamide, 5-chloro-2-[(1-chloro-2-naphthalenyl)amino]- (CA INDEX NAME)




RN 702641-25-6 CAPLUS  
 CN Benzenesulfonamide, 2-(2-naphthalenylamino)- (CA INDEX NAME)




RN 702641-26-7 CAPLUS  
 CN Benzenesulfonamide, 5-methyl-2-(2-naphthalenylamino)- (CA INDEX NAME)




RN 702641-46-1 CAPLUS  
 CN Benzeneacetic acid, 5-chloro-2-[(3-chloro-2-naphthalenyl)amino]- (CA INDEX NAME)




RN 702641-47-2 CAPLUS  
 CN Benzeneacetic acid, 2-[(3-chloro-2-naphthalenyl)amino]-5-methyl- (CA INDEX NAME)



RN 702641-57-4 CAPLUS  
 CN Benzeneacetic acid, 2-[(3-chloro-2-naphthalenyl)amino]- (CA INDEX NAME)




RN 702642-75-9 CAPLUS  
 CN Benzeneacetic acid, 2-[(1-chloro-2-naphthalenyl)amino]-5-ethyl- (CA INDEX NAME)




RN 702642-76-0 CAPLUS  
 CN Benzeneacetic acid, 5-chloro-2-[(1-chloro-6-fluoro-2-naphthalenyl)amino]-

(CA INDEX NAME)




RN 702642-78-2 CAPLUS

CN Benzeacetic acid, 5-chloro-2-[(1,6-dichloro-2-naphthalenyl)amino]- (CA INDEX NAME)




RN 702642-80-6 CAPLUS

CN Benzeacetic acid, 5-chloro-2-[(1,3-dichloro-2-naphthalenyl)amino]- (CA INDEX NAME)




RN 702642-82-8 CAPLUS

CN Benzeacetic acid, 2-[(1-chloro-2-naphthalenyl)amino]-5-cyclopropyl- (CA INDEX NAME)




RN 702642-84-0 CAPLUS


CN Benzeacetic acid, 2-[(1-chloro-6-fluoro-2-naphthalenyl)amino]-5-methyl- (CA INDEX NAME)




RN 702642-86-2 CAPLUS  
 CN Benzeacetic acid, 2-[(1-chloro-6-fluoro-2-naphthalenyl)amino]-5-ethyl-  
 (CA INDEX NAME)




RN 702642-88-4 CAPLUS  
 CN Benzeacetic acid, 5-chloro-2-[(1-fluoro-2-naphthalenyl)amino]- (CA  
 INDEX NAME)



RN 702642-90-8 CAPLUS  
 CN Benzeacetic acid, 2-[(1-fluoro-2-naphthalenyl)amino]-5-methyl- (CA  
 INDEX NAME)




RN 702642-93-1 CAPLUS  
 CN Benzeacetic acid, 2-[(1-chloro-6-fluoro-2-naphthalenyl)amino]-5-  
 cyclopropyl- (CA INDEX NAME)




RN 702642-95-3 CAPLUS


CN Benzeacetic acid, 5-chloro-2-[(1-chloro-3-fluoro-2-naphthalenyl)amino]-  
(CA INDEX NAME)




RN 702643-07-0 CAPLUS  
CN Benzeacetic acid, 5-chloro-2-[(1-chloro-7-fluoro-2-naphthalenyl)amino]-  
(CA INDEX NAME)




RN 702643-09-2 CAPLUS  
CN Benzeacetic acid, 5-chloro-2-[[1-chloro-7-(trifluoromethyl)-2-naphthalenyl]amino]- (CA INDEX NAME)




RN 702643-38-7 CAPLUS  
CN Benzeacetic acid, 2-[(3-chloro-1-fluoro-2-naphthalenyl)amino]-5-methyl-  
(CA INDEX NAME)




RN 702643-40-1 CAPLUS  
CN Benzeacetic acid, 2-[(3-chloro-2-naphthalenyl)amino]-5-ethyl- (CA INDEX NAME)




RN 702643-43-4 CAPLUS  
 CN Benzenecetic acid, 5-chloro-2-[(3-chloro-1-fluoro-2-naphthalenyl)amino]-  
 (CA INDEX NAME)




RN 702643-45-6 CAPLUS  
 CN Benzenecetic acid, 2-[(1-chloro-3-fluoro-2-naphthalenyl)amino]-5-methyl-  
 (CA INDEX NAME)



RN 702643-46-7 CAPLUS  
 CN Benzenecetic acid, 2-[(1,3-difluoro-2-naphthalenyl)amino]-5-methyl- (CA  
 INDEX NAME)



RN 702643-47-8 CAPLUS  
 CN Benzenecetic acid, 5-chloro-2-[(1,3-difluoro-2-naphthalenyl)amino]- (CA  
 INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:453231 CAPLUS  
 DOCUMENT NUMBER: 141:23422  
 TITLE: Preparation of non-steroidal FXR agonists  
 INVENTOR(S): Nicolaou, Kyriacos C.; Roecker, Anthony J.; Hughes, Robert; Pfefferkorn, Jeffrey A.  
 PATENT ASSIGNEE(S): The Scripps Research Institute, USA  
 SOURCE: PCT Int. Appl., 75 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046162	A2	20040603	WO 2003-US36195	20031114 <--
WO 2004046162	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003290796	A1	20040615	US 2002-426456P	20031114 <--
PRIORITY APPLN. INFO.:			US 2003-491185P	P 20021114 <--
			US 2003-491185P	P 20030729 <--
			WO 2003-US36195	W 20031114 <--
OTHER SOURCE(S): MARPAT 141:23422				
GI				



AB Non-steroidal N-aryl-N-arylmethyl amido and ureido compds. such as I [E1 = (C1-C8)alkyl, cyclohexyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, Ph, NH(C1-C8)alkyl; L1, L2 = H; dashed bond = single bond or double bond; X1 = CO, CH2; Y1 = H, NHZ1, NH(Z2)Z3, OZ4; A1 = aryl, heterocyclyl etc.; Z1 = H, Ph, alkyl, benzyl, benzoyl; Z2, Z3 = alkyl; Z2Z3 = cycloalkyl; Z4 = H, oxygen protecting group], were prepared for their therapeutic use as farnesoid X receptor (FXR) agonists. Thus, biaryl compound II, prepared via solid phase synthesis starting from N-(tert-butoxycarbonyl)-3-aminocinnamic acid, Merrifield Resin, 4-bromobenzaldehyde, cyclohexanoyl chloride, and 3,4-difluorobenzeneboronic acid, showed FXR activity (EC50 = 72 nM) and relative efficacy = 1.70 at 1-100 mM CDCA from a cell-based assay. The

FXR agonists are useful as therapeutic agents for the treatment of diseases linked to cholesterol, bile acids, and their metabolism and homeostasis.


IT 698357-50-5P 698359-36-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl-N-arylmethyl amido and ureido compds. as farnesoid X receptor agonists)


RN 698357-50-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[(8-methoxy-2,2-dimethyl-2H-1-benzopyran-7-yl)methyl](2-naphthalenylcarbonyl)amino]phenyl]-, methyl ester (CA INDEX NAME)



RN 698359-36-3 CAPLUS

CN 2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)(2-naphthalenylmethyl)amino]phenyl]-, methyl ester (CA INDEX NAME)



L10 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:453152 CAPLUS

DOCUMENT NUMBER: 141:17647

TITLE: N-acyl-N-arylmethylaniline acrylates as nonsteroidal

farnesoid X receptor modulators

INVENTOR(S): Downes, Michael R.; Evans, Ronald M.

PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046068	A2	20040603	WO 2003-US36137	20031114 <--



WO 2004046068 A3 20041229

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20050143449 A1 20050630 US 2003-658115 20030908 <--  
 AU 2003294264 A1 20040615 AU 2003-294264 20031114 <--  
 US 20060128764 A1 20060615 US 2005-535043 20051209 <--


PRIORITY APPLN. INFO.: US 2002-426664P P 20021115 <--  
 US 2003-658115 A2 20030908 <--  
 WO 2003-US36137 W 20031114 <--

OTHER SOURCE(S): MARPAT 141:17647  
 GI




AB A method for modulating process(es) mediated by farnesyl X receptor polypeptides comprises conducting said process(es) in the presence of title compds. [I; A = (substituted) alkyl, cycloalkyl, aryl, heteroaryl; X = CO, CH2; R = Me, Et; R1 = H, OH, alkoxy, PhCO2, mesityloxy, OCH2CO2Et; R2 = H; R3 = alkenyl, (substituted) aryl, heteroaryl, aralkenyl, heteroaralkenyl; R2R3 = atoms to form a (substituted) (unsatd.) pyran ring; R4 = H, OH; R5 = H, OH, alkoxy, aryloxy]. In a cell-based transcription assay, title compound (II) activated FXR with EC50 = 36 nM.  
 IT 1055899-02-9  
 RL: PRPH (Prophetic)  
 (N-acyl-N-arylmethylaniline acrylates as nonsteroidal farnesoid X receptor modulators)  
 RN 1055899-02-9 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Double bond geometry as shown.



IT 592524-92-0P 698357-50-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-acyl-N-arylmethylaniline acrylates as nonsteroidal farnesoid X receptor modulators)  
 RN 592524-92-0 CAPLUS  
 CN 2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)-2-naphthalenylamino]phenyl]-, methyl ester (CA INDEX NAME)



RN 698357-50-5 CAPLUS  
 CN 2-Propenoic acid, 3-[3-[(8-methoxy-2,2-dimethyl-2H-1-benzopyran-7-yl)methyl](2-naphthalenylcarbonyl)amino]phenyl]-, methyl ester (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2004:452954 CAPLUS  
 DOCUMENT NUMBER: 141:17646

TITLE: N-acyl-N-benzylaniline acrylates as nonsteroidal  
farnesoid X receptor (FXR) modulators  
INVENTOR(S): Downes, Michael R.; Evans, Ronald Mark; Hughes,  
Robert; Nicolaou, Kyriacos C.; Roecker, Anthony J.  
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA; The  
Scripps Research Institute  
SOURCE: PCT Int. Appl., 62 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045511	A2	20040603	WO 2003-US36123	20031114 <--
WO 2004045511	A3	20040708		
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
US 20050143449	A1	20050630	US 2003-658115	20030908 <--
AU 2003290778	A1	20040615	AU 2003-290778	20031114 <--
US 20060223879	A1	20061005	US 2005-535041	20051228 <--
PRIORITY APPLN. INFO.:			US 2002-426664P	P 20021115 <--
			US 2003-658115	A2 20030908 <--
			WO 2003-US36123	W 20031114 <--
OTHER SOURCE(S):	MARPAT 141:17646			
GI				



AB Title compds. [I; A = (substituted) alkyl, cycloalkyl, aryl, heteroaryl; X  
= CO, CH2; R = Me, Et; R1 = H, OH, alkoxy, PhCO2, mesityloxy, OCH2CO2Et;

R2 = H; R3 = alkenyl, (substituted) aryl, heteroaryl, aralkenyl, heteroaralkenyl; R2R3 = atoms to form a substituted (unsatd.) pyran ring; R4 = H, OH; R5 = H, OH, alkoxy, aryloxy], are claimed. Thus, benzopyran derivative (II) activated FXR receptors with EC50 = 358 nM.


IT 592524-92-QP 698357-50-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylbenzylaniline acrylates as nonsteroidal farnesoid X receptor (FXR) modulators)


RN 592524-92-0 CAPLUS

CN 2-Propenoic acid, 3-[3-[(cyclohexylcarbonyl)-2-naphthalenylaminophenyl]-, methyl ester (CA INDEX NAME)



RN 698357-50-5 CAPLUS

CN 2-Propenoic acid, 3-[3-[(8-methoxy-2,2-dimethyl-2H-1-benzopyran-7-yl)methyl](2-naphthalenylcarbonyl)aminophenyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:255113 CAPLUS

DOCUMENT NUMBER: 138:271392

TITLE: Benzenebutyric acids and their derivatives as inhibitors of matrix metalloproteinases

INVENTOR(S): Purchase, Claude Forsey, Jr.; Roth, Bruce David; White, Andrew David

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: U.S., 38 pp. CODEN: USXXAM



DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
US 6541521	B1	20030401	US 1999-351549	19990712
US 20020161050	A1	20021031	US 2001-23288	20011217 <--
US 6624196	B2	20030923		
PRIORITY APPLN. INFO.:			US 1999-351549	A3 19990712 <--
OTHER SOURCE(S):	MARPAT	138:271392		

GI




AB Title compds. I and their isomers and pharmaceutically acceptable salts are disclosed [wherein: R1 = H, (cyclo)alkyl, (hetero)aryl, (hetero)arylalkyl, heterocyclyl(alkyl); X = (un)substituted COCH2, CONH, NHCO, COO, OCO, CO, CH(OH), C(:NH)NH, OCOO, OCONH, NHCOO, NHCONH, C(:S)NH, NHC(:S), C(:S)O, OC(:S), OC(:S)O, OC(:S)NH, NHC(:S)O, NHC(:S)NH; m = 0-4; Z = CO, (un)substituted C(:NOH) or CH(OH), CHF, CF2; R2, R2a, R3, R3a = (independently) H, F, R5, (un)substituted -alkyl-R5, (un)substituted -NHCO-alkyl or -NH-alkyl; R4 = SH, OH, alkoxy, aralkoxy, cycloalkoxy, etc.; R5 = H, (hetero)aryl, heterocyclyl, phthalimido, 2,3-naphthylimido, indol-3-yl, imidazol-4-yl, 2-, 3-, or 4-pyridyl, 2,4-dioxo-1,5,5-trimethylimidazolidin-3-yl, or an (un)natural amino acid sidechain]. Novel compds. and derivs. are described, as well as methods for their preparation, and pharmaceutical compns. containing them. Compds. I

are


useful as inhibitors of matrix metalloproteinases (MMPs), particularly gelatinase A (MMP-2), collagenase-3 (MMP-13), and stromelysin-1 (MMP-3). I are thereby useful for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy. A total of 36 compds. I were prepared and tested against the 3 aforementioned MMPs. For instance, Friedel-Crafts acylation of acetanilide by succinic anhydride in DMF in

the presence of AlCl<sub>3</sub> gave 4-(AcNH)C<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, which was deacetylated with aqueous HCl and then treated with Me<sub>3</sub>SiCH<sub>2</sub>N<sub>2</sub> in PhMe/MeOH mixture to give 4-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me. Amidation of this amine with 4-MeOC<sub>6</sub>H<sub>4</sub>COCl using 4-morpholinomethyl polystyrene resin gave title compound II. Compound II inhibited MMP catalytic domains (CD) in vitro as follows (IC<sub>50</sub>): MMP-2CD 0.07, MMP-3CD 0.34, and MMP-13CD 9.8 μM.

IT 474018-44-5P, 4-[4-[(Naphthyl-2-ylcarbonyl)aminophenyl]-4-oxobutyric acid 474020-99-0P,  
4-Hydroxyimino-4-[4-[(naphth-2-ylcarbonyl)aminophenyl]butyric acid  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of benzenebutyric acids and derivs. as inhibitors of matrix metalloproteinases)  
RN 474018-44-5 CAPLUS  
CN Benzenebutanoic acid, 4-[(2-naphthalenylcarbonyl)amino]-γ-oxo- (CA INDEX NAME)



RN 474020-99-0 CAPLUS  
CN Benzenebutanoic acid, γ-(hydroxyimino)-4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:154382 CAPLUS

DOCUMENT NUMBER: 138:187795

TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E<sub>2</sub> (PEG<sub>2</sub>) receptors  
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio  
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 1009 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003016254	A1	20030227	WO 2002-JP8120	20020808 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457468	A1	20030227	CA 2002-2457468	20020808 <--
AU 2002323916	A1	20030303	AU 2002-323916	20020808 <--
EP 1431267	A1	20040623	EP 2002-755874	20020808 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011810	A	20040824	BR 2002-11810	20020808 <--
CN 1551866	A	20041201	CN 2002-817376	20020808 <--
HU 2004001963	A2	20050128	HU 2004-1963	20020808 <--
HU 2004001963	A3	20060130		
NZ 531153	A	20051028	NZ 2002-531153	20020808 <--
NZ 541950	A	20070223	NZ 2002-541950	20020808 <--
RU 2315746	C2	20080127	RU 2004-106623	20020808 <--
CN 101284773	A	20081015	CN 2008-10002260	20020808 <--
ZA 2004000973	A	20050104	ZA 2004-973	20040205 <--
NO 2004000564	A	20040510	NO 2004-564	20040206 <--
MX 2004001253	A	20040603	MX 2004-1253	20040209 <--
US 20060258728	A1	20061116	US 2004-486220	20040909 <--
US 7491748	B2	20090217		

PRIORITY APPLN. INFO.:

JP 2001-241867	A	20010809 <--
CN 2002-817376	A3	20020808 <--
WO 2002-JP8120	W	20020808 <--

OTHER SOURCE(S): MARPAT 138:187795  
GI



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo, m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHC(O), etc.); D = an linking

chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic heterocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propanamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propanamide, (thiophenylmethylphenyl)propanamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropanamide, (pyrazolylmethylphenoxy)acetamide, (phenoxyethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[(2-(Naphthalen-1-yl)propanoyl)amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, EP2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038  $\mu$ M, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT


499154-34-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499154-34-6 CAPLUS

CN 2-Propenoic acid, 3-[2-[methyl[2-(2-naphthalenyl)ethyl]amino]-4-(phenoxyethyl)phenyl]-, ethyl ester (CA INDEX NAME)




IT 499154-35-7P 499154-36-8P 499154-38-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)


RN 499154-35-7 CAPLUS

CN Benzenepropanoic acid, 2-[methyl[2-(2-naphthalenyl)ethyl]amino]-4-(phenoxyethyl)-, ethyl ester (CA INDEX NAME)




RN 499154-36-8 CAPLUS

CN Benzenepropanoic acid, 2-[methyl[2-(2-naphthalenyl)ethyl]amino]-4-(phenoxyethyl)- (CA INDEX NAME)



RN 499154-38-0 CAPLUS

CN Benzenepropanoic acid, 2-[acetyl[2-(2-naphthalenyl)ethyl]amino]-4-(phenoxymethyl)- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:833521 CAPLUS

DOCUMENT NUMBER: 137:337683

TITLE: Preparation of benzenebutyric acids as inhibitors of matrix metalloproteinases

INVENTOR(S): Purchase, Claude Forsey; Roth, Bruce David; White, Andrew David

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: U.S. Pat. Appl. Publ., 43 pp., Division of U. S. Ser. No. 351,549.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020161050	A1	20021031	US 2001-23288	20011217 <--
US 6624196	B2	20030923		
US 6541521	B1	20030401	US 1999-351549	19990712
PRIORITY APPLN. INFO.:			US 1999-351549	A3 19990712 <--
OTHER SOURCE(S):		MARPAT 137:337683		

GI



I



II

AB The title compds. with general formula of I [wherein R1 = H, (cyclo)alkyl, (hetero)aryl, (hetero)arylalkyl, or heterocyclyl(alkyl); R2, R2a, R3, and R3a = independently H, F, R5, NR7CO-alkyl, alkanoyl(oxy), alkoxy carbonyl, alkanoylthio, NR7-alkyl, alkylsulfinyl, alkylsulfonyl(amino), CN, CF3, or (un)substituted alkyl-R5; R5 = H, (hetero)aryl, heterocyclyl, N-naphthalimido, N-2,3-naphthylimido, indol-3-yl, imidazol-4-yl, pyridyl, 2,4-dioxo-1,5,5-trimethylimidazolidin-3-yl, or a side chain of an (un)naturally occurring amino acid; R4 = SH, OR4a, or NHOR4a; R4a = H, (aryl)alkyl, cycloalkyl, or aryloxy methyl; X = COCH2, CONR6, NR6CO, CO2, OCO, CO, CH(OH), C(=NH)NR6, OCO2, OCONR6, NR6CO2, NR6CONR6a, CSNR6, NR6CS, CSO, OCS, OCSO, OCSNR6, NR6CSO, or NR6CSNR6a; R6 and R6a = independently H or CH3; or R1 and R6 together form a ring containing (un)substituted 4-7 carbons, etc.; Z = CO, CN(OR7), C(OH)R7, CHF, or CF2; R7 = H or alkyl; m = 0-4; or isomers and pharmaceutically acceptable salts thereof] where prepared as inhibitors of matrix metalloproteinases (MMP), particularly gelatinase A, collagenase-3, and stromelysin-1. For example, reaction of acetanilide and succinic anhydride in DMF in the presence of AlCl3 gave 4-(4-acetylaminophenyl)-4-oxobutyric acid. The above compound was treated with 1.0 M aqueous HCl, followed by 50% weight/weight aqueous NaOH, and again


by 1.0 M aqueous HCl to give 4-(4-aminophenyl)-4-oxobutyric acid. Subsequent esterification, amidation, and hydrolysis of the above compound afforded 4-[4-(4-methylbenzoylamino)phenyl]-4-oxobutyric acid (II). II showed the activity vs. MMP-2CD, MMP-3CD, and MMP-13CD with IC50 values of 0.22  $\mu$ M, 1.55  $\mu$ M, and 5.8  $\mu$ M, resp. I are useful for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy (no data).

IT 474018-44-5P 474020-99-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP inhibitor; preparation of benzenebutyric acids as inhibitors of matrix metalloproteinases)


RN 474018-44-5 CAPLUS

CN Benzenebutanoic acid, 4-[(2-naphthalenylcarbonyl)amino]- $\gamma$ -oxo- (CA INDEX NAME)



RN 474020-99-0 CAPLUS

CN Benzenebutanoic acid,  $\gamma$ -(hydroxyimino)-4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



L10 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:313485 CAPLUS

DOCUMENT NUMBER: 136:332596

TITLE: Organic electroluminescent device containing hole-transporting polyester layers

INVENTOR(S): Seki, Mieko; Okuda, Daisuke; Yoneyama, Hiroto; Hirose, Eiichi; Mashimo, Kiyokazu; Agata, Takashi; Sato, Katsuhiro

PATENT ASSIGNEE(S): Fuji Xerox Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokyo Koho, 26 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002124388	A	20020426	JP 2000-313190	20001013
JP 3893869	B2	20070314		
US 20020182440	A1	20021205	US 2001-973800	20011011 <--
US 6652995	B2	20031125		

PRIORITY APPLN. INFO.: JP 2000-313190 A 20001013 <--

AB The invention relates to an organic electroluminescent device comprising the hole-transporting layer made of the polyesters containing  $\geq 1$  repeating partial structures represented by  $-\text{TC6H4N}(\text{Ar})\text{X}[\text{N}(\text{Ar})\text{C6H4}]_k\text{T}-$  and/or  $-\text{TC6H4}-\text{C6H4N}(\text{Ar})\text{X}[\text{N}(\text{Ar})\text{C6H4}-\text{C6H4}]_k\text{T}-$  [Ar = polyarom. (un)substituted with 3-10 aromatic rings or monovalent condensed aromatic (un)substituted with 2-10 aromatic rings; X = (un)substituted divalent aromatic group; T = C1-6 divalent straight hydrocarbyl; or C2-10 divalent branched hydrocarbyl; k = 0 or 1].

IT 415715-30-9 415715-32-1 415715-41-2

415715-43-4

RL: DEV (Device component use); USES (Uses)

(organic electroluminescent device containing hole-transporting polyester layers)


RN 415715-30-9 CAPLUS

CN Benzenepropanoic acid, 4,4'-[1,1'-biphenyl]-4,4'-diylbis(2-naphthalenylimino)]bis-, dimethyl ester, polymer with 1,2-ethanediol (9CI)  
(CA INDEX NAME)

CM 1

CRN 415715-29-6

CMF C52 H44 N2 O4



CM 2


CRN 107-21-1

CMF C2 H6 O2



RN 415715-32-1 CAPLUS

CN Poly[oxy-1,2-ethanediyl oxy(1-oxo-1,3-propanediyl)-1,4-phenylene(2-naphthalenylimino)[1,1'-biphenyl]-4,4'-diyl(2-naphthalenylimino)-1,4-phenylene(3-oxo-1,3-propanediyl)] (9CI) (CA INDEX NAME)




RN 415715-41-2 CAPLUS

CN Benzenepropanoic acid, 4,4'-[[1,1':4',1''-terphenyl]-4,4''-diylbis(2-naphthalenylimino)]bis-, dimethyl ester, polymer with 1,2-ethanediol (9CI) (CA INDEX NAME)

CM 1

CRN 415715-40-1

CMF C58 H48 N2 O4



CM 2

CRN 107-21-1


CMF C2 H6 O2

HO-CH<sub>2</sub>-CH<sub>2</sub>-OH

RN 415715-43-4 CAPLUS

CN Poly[oxy-1,2-ethanediyoxy(1-oxo-1,3-propanediyl)-1,4-phenylene(2-naphthalenylimino)[1,1':4',1''-terphenyl]-4,4''-diyl(2-naphthalenylimino)-1,4-phenylene(3-oxo-1,3-propanediyl)] (9CI) (CA INDEX NAME)

PAGE 1-A



L10 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:256222 CAPLUS  
 DOCUMENT NUMBER: 136:294651  
 TITLE: Preparation of aryl-substituted N-hydroxy amides with  
 amide linkages as HDAC inhibitors for treatment of  
 proliferative conditions  
 INVENTOR(S): Watkins, Clare J.; Romero-Martin, Maria-Rosario;  
 Moore, Kathryn G.; Ritchie, James; Finn, Paul W.;  
 Kalvinsh, Ivars; Loza, Einars; Starchenkov, Igor;  
 Dikovska, Klara; Bokaldere, Rasma Melita; Gailite,  
 Viija; Vorona, Maxim; Andrianov, Victor; Lolya, Daina;  
 Semenikhina, Valentina; Amolins, Andris; Harris, C.  
 John; Duffy, James E. S.  
 PATENT ASSIGNEE(S): Prolifix Limited, UK  
 SOURCE: PCT Int. Appl., 346 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026696	A1	20020404	WO 2001-GB4329	20010927 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2423868	A1	20020404	CA 2001-2423868	20010927 <--
AU 2001090134	A	20020408	AU 2001-90134	20010927 <--
EP 1335898	A1	20030820	EP 2001-970014	20010927 <--
EP 1335898	B1	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509941	T	20040402	JP 2002-531082	20010927 <--
EP 1598067	A1	20051123	EP 2005-15737	20010927 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, FI, CY, TR				
AT 310719	T	20051215	AT 2001-970014	20010927	<--
ES 2257441	T3	20060801	ES 2001-970014	20010927	<--
US 20040092598	A1	20040513	US 2003-381791	20030827	<--
PRIORITY APPLN. INFO.:			GB 2000-23985	A	20000929 <--
			US 2001-297785P	P	20010614 <--
			EP 2001-970014	A3	20010927 <--
			WO 2001-GB4329	W	20010927 <--


OTHER SOURCE(S): MARPAT 136:294651

AB The title comps. A01JQ2CONHOH [I; wherein A = aryl group; Q1 = aryl leader group having a backbone of at least 2 C atoms; J = NR1CO or CONR1; R1 = amido substituent; Q2 = acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemical protected forms, and prodrugs thereof] were prepared via solution phase and solid phase synthetic methods as histone deacetylase (HDAC) inhibitors for treatment of proliferative conditions, such as cancer and psoriasis. For example, 6-aminocaproic acid Me ester•HCl was coupled with 2-naphthoyl chloride in the presence of diisopropyl ethylamine in DMF to give the amide. Deesterification (79%), followed by conversion to the N-hydroxyamide using HONH2•HCl in the presence of 1,1'-carbonyldiimidazole in THF, afforded naphthalene-2-carboxylic acid (5-hydroxycarbamoylpentyl)amide II (PX105687) in 40% yield. The latter inhibited recombinant HDAC1 and HDAC2 with IC50 values of 33 nM and 29 nM, resp., and inhibited cell proliferation against the human cervical adenocarcinoma (HeLa) cell line using cell proliferation reagent WST-1 with IC50 of 1.1 nM. Structure-activity relationship studies showed superior activity for I when (1) the backbone of Q1 had > 1 carbon atoms, and (2) the alkylene group Q2 had > 5 carbon atoms.

IT 406725-58-4P, 3-[4-[(Naphthalene-2-carbonyl)amino]phenyl]acrylic acid methyl ester 406725-59-5P, 3-[4-[(Naphthalene-2-carbonyl)amino]phenyl]acrylic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)


RN 406725-58-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[(2-naphthalenylcarbonyl)amino]phenyl]-, methyl ester (CA INDEX NAME)



RN 406725-59-5 CAPLUS

CN 2-Propenoic acid, 3-[4-[(2-naphthalenylcarbonyl)amino]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:742139 CAPLUS

DOCUMENT NUMBER: 133:310145

TITLE: Preparation of modified pentapeptide antagonists of

the atrial natriuretic peptide clearance receptor

INVENTOR(S): Veale, Chris Allan; Edwards, Philip Duke; Jacobs, Robert Toms; Davenport, Timothy Wayne; Warwick, Paul James

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061631	A1	20001019	WO 2000-GB1319	20000407 <--

W: JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1999-128890P P 19990412 &lt;--

OTHER SOURCE(S): MARPAT 133:310145

AB Compds. R5-R4-R3-CH2CONR2-X-NR1CHR6CO[NHCH(CH2CO2H)CO-R7-R8-(S)] [X = CR1:CH, CHR1CO (I), or CR1CO; R12 = CH2CH2, CH2CH2CH2, :CHCH:CH, N:CH; R2 = H, Me; R3 = CH2CH2CH2, (E)-CH:CHCONH, CH2CH2CONH, phenylene, or a single bond; R4 = NHCO, CONH, SO2NH; R5 = 1- or 2-naphthyl, CH2CH2NHCH2CH:CHPh, CH2CH2Ph, CH:CHPh, 2-, 3-, 4-, or 6-quinolyl, 3-isoquinolyl, 2-quinoxaline, 5-chloro-2-indolyl, 2-indolyl, (un)substituted Ph, CH2CH2CH2Ph, 6-quinolylcarbonyl, 2-quinoxalinecarbonyl, 5-chloro-2-benzimidazolyl, fluorenylmethoxycarbonyl, 4-chlorobenzyl, 4-methylbenzyl, 3-quinoxalyl, 3,4-difluorophenyl, 4-fluorophenyl; R6 = iso-Bu, sec-butyl; R7 = N-methylglycine, NHCH2CH2NHCO, L- or D-arginine or -ornithine, histidine, citrulline, proline, etc.; R8 = L- or D-isoleucine-NH2, CH2-cyclopentyl, CH2-2-furanyl, tert-butylglycine-NH2, Bu, etc.] were prepared as antagonists of the atrial natriuretic peptide clearance receptor. Thus, inhibitory test data are tabulated for 156 compds. of the invention, including I [R12 = CH2CH2 (S-configuration); R2 = H; R3 = p-phenylene; R4 = CONH; R5 = 2-naphthyl; R6 = s-Bu (S-configuration); R7 = N-MeGly; R8 = Ile-NH2] (K1 = 2.17 nM).

IT 160346-06-5P 301840-38-0P 301840-40-4P


301840-42-6P 301840-45-9P 301840-46-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor)


RN 160346-06-5 CAPLUS

CN Benzeneacetic acid, 4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)




RN 301840-38-0 CAPLUS

CN Benzeneacetic acid, 4-[(2-naphthalenylcarbonyl)amino]-, methyl ester (CA INDEX NAME)




RN 301840-40-4 CAPLUS

CN Benzeneacetic acid, 3-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)




RN 301840-42-6 CAPLUS

CN Benzeneacetic acid, 3-[(2-naphthalenylcarbonyl)amino]-, methyl ester (CA INDEX NAME)




RN 301840-45-9 CAPLUS

CN Benzeneacetic acid, 2-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



RN 301840-46-0 CAPLUS

CN Benzeneacetic acid, 2-[(2-naphthalenylcarbonyl)amino]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:492070 CAPLUS  
 DOCUMENT NUMBER: 133:109955  
 TITLE: Amino acid derivatives and compositions therewith for delivering active agents  
 INVENTOR(S): Leone-Bay, Andrea; Ho, Koc-kan; Sarubbi, Donald J.; Leipold, Harry R.  
 PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA  
 SOURCE: U.S., 44 pp., Cont.-in-part of PCT 9736480.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 30  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6090958	A	20000718	US 1997-797816	19970207 <--
AT 357243	T	20070415	AT 1996-913778	19960401 <--
EP 1792624	A1	20070606	EP 2007-4042	19960401 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, SI				
ES 2284168	T3	20071101	ES 1996-913778	19960401 <--
CZ 299295	B6	20080611	CZ 1997-3073	19960401 <--
WO 9736480	A1	19971009	WO 1997-US5128	19970318 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2279331	A1	19980813	CA 1998-2279331	19980206 <--
CA 2319672	A1	19980813	CA 1998-2319672	19980206 <--
CA 2319680	A1	19980813	CA 1998-2319680	19980206 <--
WO 9834632	A1	19980813	WO 1998-US2619	19980206 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862756	A	19980826	AU 1998-62756	19980206 <--
AU 738735	B2	20010927		
EP 993831	A2	20000419	EP 1999-117292	19980206 <--
EP 993831	A3	20010502		
EP 993831	B1	20080109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1015008	A1	20000705	EP 1998-905042	19980206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1093819	A2	20010425	EP 2000-122704	19980206 <--
EP 1093819	A3	20030514		
EP 1093819	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

## IE, FI

JP 2001513080	T	20010828	JP 1998-535034	19980206 <--
NZ 337131	A	20010831	NZ 1998-337131	19980206 <--
AT 324907	T	20060615	AT 2000-122704	19980206 <--
PT 1093819	T	20060929	PT 2000-122704	19980206 <--
AT 383169	T	20080115	AT 1999-117292	19980206 <--
MX 9907290	A	20000531	MX 1999-7290	19990806 <--
NZ 507275	A	20011130	NZ 2000-507275	20001003 <--
NZ 507276	A	20020201	NZ 2000-507276	20001003 <--
JP 2001131090	A	20010515	JP 2000-311231	20001011 <--
JP 3964613	B2	20070822		
JP 2001139494	A	20010522	JP 2000-311230	20001011 <--
JP 4012679	B2	20071121		
AU 771024	B2	20040311	AU 2000-72261	20001214 <--
AU 771434	B2	20040325	AU 2000-72260	20001214 <--
HK 1037132	A1	20061103	HK 2001-107390	20011023 <--
AU 2004202745	A1	20040923	AU 2004-202745	20040623 <--
US 20050186176	A1	20050825	US 2005-104173	20050411 <--
US 7417022	B2	20080826		

## PRIORITY APPLN. INFO.:

US 1996-17902P	P	19960329 <--
WO 1997-US5128	A2	19970318 <--
US 1995-414654	A	19950331 <--
US 1995-3111P	P	19950901 <--
US 1996-17902	A1	19960329 <--
EP 1996-913778	A3	19960401 <--
US 1997-796334	A	19970207 <--
US 1997-796335	A	19970207 <--
US 1997-796336	A	19970207 <--
US 1997-796337	A	19970207 <--
US 1997-796338	A	19970207 <--
US 1997-796339	A	19970207 <--
US 1997-796340	A	19970207 <--
US 1997-796341	A	19970207 <--
US 1997-797100	A	19970207 <--
US 1997-797813	A	19970207 <--
US 1997-797816	A	19970207 <--
US 1997-797817	A	19970207 <--
US 1997-797820	A	19970207 <--
US 1997-820694	A1	19970318 <--
AU 1998-62756	A3	19980206 <--
CA 1998-2279331	A3	19980206 <--
EP 1998-905042	A3	19980206 <--
EP 1999-117292	A3	19980206 <--
JP 1998-535034	A3	19980206 <--
NZ 1998-337131	A1	19980206 <--
WO 1998-US2619	W	19980206 <--
AU 2000-72260	A3	20001214 <--
US 2001-5511	A1	20011107 <--


AB Carrier compds., especially amino acid derivs., and compns. therewith which are useful in the delivery of active agents, e.g. peptides, mucopolysaccharides, carbohydrates, and lipids, are provided. Methods of administration and preparation are provided as well. An intracolonic dosing composition containing parathyroid hormone 25 µg/kg, 4-[4-(phenoxyacetyl)aminophenyl]butyric acid as carrier 100 mg/kg in 25% aqueous propylene glycol was prepared

IT 209961-45-5P 209961-83-1P 209961-85-3P  
284028-07-5P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid derivs. as drug carriers for biol. active components)


RN 209961-45-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[1-hydroxy-2-naphthalenyl]carbonyl]amino]- (CA


INDEX NAME)




RN 209961-83-1 CAPLUS  
CN Benzenebutanoic acid, 4-[[ (3-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



RN 209961-85-3 CAPLUS  
CN Benzenepropanoic acid, 4-[[ (3-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



RN 284028-07-5 CAPLUS  
CN Benzenebutanoic acid, 4-[[ (1,4-dihydro-1-oxo-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L10 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:144899 CAPLUS  
DOCUMENT NUMBER: 132:189658  
TITLE: Amino acid derivative and peptide anti-cancer compounds and methods  
INVENTOR(S): Stewart, John M.; Chan, Daniel C. F.; Gera, Lojos; York, Eunice; Bunn, Paul  
PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011022	A1	20000302	WO 1999-US19381	19990820 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 6388054 B1 20020514 US 1999-378019 19990819 <-- AU 2000015959 A 20000314 AU 2000-15959 19990820 <--				
PRIORITY APPLN. INFO.:				
US 1998-97210P P 19980820 <-- US 1999-141169P P 19990625 <-- US 1999-378019 A 19990819 <-- WO 1999-US19381 W 19990820 <--				

OTHER SOURCE(S): MARPAT 132:189658

AB The invention provides amino acid derivative and peptidic compds. useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula [ACA]<sub>n</sub>X [X = linker group with 2-5 functional groups or is absent; n = 1; ACA as described in the invention (Markush included)].

IT 259884-52-1P 259884-53-2P 259884-54-3P  
 259884-55-4P 259884-56-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide and non-peptide anti-cancer compds. and methods)

RN 259884-52-1 CAPLUS

CN Phenylalanine, N-(aminoiminomethyl)-4-[[[(2S)-2-[(aminoiminomethyl)amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259884-53-2 CAPLUS

CN Benzeneacetic acid, 4-[[[(2S)-2-[(cyclohexylimino)(cyclohexylimino)methyl]amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 259884-54-3 CAPLUS

CN Benzeneacetic acid, 4-[[[(2S)-2-[(aminoiminomethyl)amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 259884-55-4 CAPLUS


CN Benzeneacetic acid, 4-[[[(2R)-2-[[[(cyclohexylamino)(cyclohexylimino)methyl]amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 259884-56-5 CAPLUS  
 CN Benzeneacetic acid, 4-[[1(2R)-2-[(aminoiminomethyl)amino]-3-(2-naphthalenyl)-1-oxopropyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:27805 CAPLUS  
 DOCUMENT NUMBER: 130:95843  
 TITLE: Preparation of cyclopentylcarbonylamino acid as inhibitors of  $\alpha 4\beta 1$  mediated cell adhesion  
 INVENTOR(S): Lobl, Thomas J.; Rishton, Gil; Teegarden, Bradley; Polinsky, Alex; Yamagishi, Masafumi; Tanis, Steven P.; Fisher, Jed F.; Thomas, Edward W.; Chruciel, Robert A.  
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan; Pharmacia & Upjohn Company  
 SOURCE: PCT Int. Appl., 342 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858902	A1	19981230	WO 1998-US13064	19980623 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9881633	A	19990104	AU 1998-81633	19980623 <--
EP 991619	A1	20000412	EP 1998-931521	19980623 <--
EP 991619	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001517246	T	20011002	JP 1999-504997	19980623 <--
US 6482849	B1	20021119	US 1998-102584	19980623 <--
AT 249421	T	20030915	AT 1998-931521	19980623 <--
PT 991619	T	20040227	PT 1998-931521	19980623 <--
ES 2206953	T3	20040516	ES 1998-931521	19980623 <--
US 20030130349	A1	20030710	US 2002-193137	20020712 <--
US 6596752	B1	20030722		
PRIORITY APPLN. INFO.:			US 1997-50515P	P 19970623 <--
			US 1998-102584	A3 19980623 <--
			WO 1998-US13064	W 19980623 <--


OTHER SOURCE(S): MARPAT 130:95843

GI



- AB Title compds. [I; n = 0, 1; R<sub>1</sub> = H, CH<sub>3</sub>; R<sub>2</sub> = CN, CO<sub>2</sub>H, CONH<sub>2</sub>, CONHOCH<sub>2</sub>Ph, NHC(O)CH<sub>2</sub>Ph, etc.; R<sub>3</sub> = H, CH<sub>3</sub>; X = CH, CO; R<sub>4</sub> = H, alkyl; R<sub>5</sub> = CO<sub>2</sub>H, CONH<sub>2</sub>, COOR, etc.; R = alkyl; R<sub>6</sub> = aryl, heteroaryl, arylcarbonyl, aarylcarbonylaminoalkyl, etc.], a pharmaceutically acceptable salt, a stereoisomer thereof are prepared as inhibitors of α<sub>4</sub>β<sub>1</sub> mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing α<sub>4</sub>β<sub>1</sub> adhesion mediated conditions in human such as inflammatory diseases. Thus, (1S-cis)-N-[(3-carboxy-2,2,3-trimethylcyclopentyl)carbonyl]-O-(phenylmethyl)-L-tyrosine was prepared and assayed for inhibition of β<sub>1</sub>-mediated cell adhesion in vitro.
- IT 219495-10-0P 219495-11-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclopentylcarbonylamino acid as inhibitors of α<sub>4</sub>β<sub>1</sub> mediated cell adhesion)
- RN 219495-10-0 CAPLUS
- CN L-Phenylalanine, N-[(1S,3R)-3-carboxy-2,2,3-trimethylcyclopentyl]carbonyl]-4-[(2-naphthalenylcarbonyl)amino]-, α-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219495-11-1 CAPLUS

CN L-Phenylalanine, N-[[[(1S,3R)-3-carboxy-2,2,3-trimethylcyclopentyl]carbonyl]-4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:550404 CAPLUS

DOCUMENT NUMBER: 129:175441

ORIGINAL REFERENCE NO.: 129:35660h,35661a

TITLE: Preparation of tetrahydronaphthylalkenoyloxy- and -aminobenzoates and analogs for treatment of cellular differentiation and proliferation disorders

INVENTOR(S): Bernardon, Jean-Michel

PATENT ASSIGNEE(S): Centre International de Recherches Dermatologiques Galderma (C.I.R.D. Galderma), Fr.

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834909	A1	19980813	WO 1998-FR248	19980209 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,  
 LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,  
 VN, YU  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG  
 FR 2759368 A1 19980814 FR 1997-1501 19970210  
 FR 2759368 B1 20010601  
 CA 2253221 A1 19980813 CA 1998-2253221 19980209 <--  
 AU 9866265 A 19980826 AU 1998-66265 19980209 <--  
 AU 718198 B2 20000406  
 EP 901462 A1 19990317 EP 1998-908154 19980209 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI  
 JP 11507960 T 19990713 JP 1998-533895 19980209 <--  
 US 6326510 B1 20011204 US 1999-171098 19990108 <--  
 PRIORITY APPLN. INFO.: FR 1997-1501 A 19970210 <--  
 WO 1998-FR248 W 19980209 <--


OTHER SOURCE(S): MARPAT 129:175441

AB R323Z21R1 [R1 = Me, CH2OR5, OR5, COR6; R3 = (annulated)(un)substituted  
 Ph; R5 = H, alkyl, alkanoyl; R6 = H, alkyl, OH, alkoxy, etc.; Z1 = bond,  
 CH2, CH:CH, C.tplbond.C, etc.; Z2 = (un)substituted phenylene, furandiyl,  
 thiophenediyl, pyridinediyl; Z3 = CH:CHCO2, C.tplbond.CCO2, CONH, etc.]  
 were prepared for treatment of cellular differentiation and proliferation  
 disorders (no data). Thus, 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-  
 naphthalenecarboxaldehyde was condensed with (EtO)2P(O)CH2CO2Et and the  
 product converted in 4 steps to 4-[3-(5,6,7,8-tetrahydro-5,5,8,8-  
 tetramethyl-2-naphthyl)acryloyloxy]benzoic acid.

IT 211559-40-9P 211559-53-4P 211559-55-6P  
 211559-61-4P 211559-63-6P 211559-65-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tetrahydronaphthylalkenoyloxy- and -aminobenzoates and  
 analogs for treatment of cellular differentiation and proliferation  
 disorders)


RN 211559-40-9 CAPLUS

CN 2-Propenoic acid, 3-[2-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-  
 naphthalenyl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 211559-53-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-  
 naphthalenyl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)




RN 211559-55-6 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 211559-61-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 211559-63-6 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 211559-65-8 CAPLUS


CN 2-Propenoic acid, 3-[3-[[[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]amino]phenyl]- (CA INDEX NAME)



IT 211560-08-6P 211560-10-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of tetrahydronaphthylalkenoyloxy- and -aminobenzoates and analogs for treatment of cellular differentiation and proliferation disorders)  
 RN 211560-08-6 CAPLUS  
 CN 2-Propenoic acid, 3-[2-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



RN 211560-10-0 CAPLUS  
 CN 2-Propenoic acid, 3-[3-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carbonyl]amino]phenyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:548547 CAPLUS  
 DOCUMENT NUMBER: 129:180147  
 ORIGINAL REFERENCE NO.: 129:36505a,36508a  
 TITLE: Compounds and compositions for delivering active agents  
 INVENTOR(S): Leone-Bay, Andrea; et al.  
 PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA  
 SOURCE: PCT Int. Appl., 147 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 30  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834632	A1	19980813	WO 1998-US2619	19980206 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5773647	A	19980630	US 1997-796337	19970207
US 5776888	A	19980707	US 1997-796338	19970207
US 5804688	A	19980908	US 1997-796339	19970207
US 5876710	A	19990302	US 1997-796335	19970207
US 5879681	A	19990309	US 1997-796334	19970207
US 5939381	A	19990817	US 1997-796340	19970207
US 5990166	A	19991123	US 1997-797820	19970207
US 6051561	A	20000418	US 1997-797813	19970207
US 6060513	A	20000509	US 1997-797817	19970207
US 6090958	A	20000718	US 1997-797816	19970207 <--
US 6313088	B1	20011106	US 1997-797100	19970207
US 6358504	B1	20020319	US 1997-796336	19970207
CA 2279331	A1	19980813	CA 1998-2279331	19980206 <--
AU 9862756	A	19980826	AU 1998-62756	19980206 <--
AU 738735	B2	20010927		
EP 1015008	A1	20000705	EP 1998-905042	19980206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513080	T	20010828	JP 1998-535034	19980206 <--
NZ 337131	A	20010831	NZ 1998-337131	19980206 <--
MX 9907290	A	20000531	MX 1999-7290	19990806 <--
AU 771024	B2	20040311	AU 2000-72261	20001214 <--
AU 771434	B2	20040325	AU 2000-72260	20001214 <--
US 20020119910	A1	20020829	US 2000-746548	20001219 <--
US 20030008900	A1	20030109	US 2001-1731	20011031 <--
US 6525020	B2	20030225		
US 20030235612	A1	20031225	US 2003-373582	20030224 <--
US 7125910	B2	20061024		
US 20040022856	A1	20040205	US 2003-395685	20030324 <--
US 7071214	B2	20060704		
AU 2004202745	A1	20040923	AU 2004-202745	20040623 <--
US 20060166859	A1	20060727	US 2006-354045	20060213 <--
PRIORITY APPLN. INFO.:				
			US 1997-796334	A1 19970207 <--
			US 1997-796335	A1 19970207 <--
			US 1997-796336	A1 19970207 <--
			US 1997-796337	A1 19970207 <--
			US 1997-796338	A1 19970207 <--
			US 1997-796339	A1 19970207 <--
			US 1997-796340	A1 19970207 <--
			US 1997-796341	A1 19970207 <--
			US 1997-797100	A1 19970207 <--
			US 1997-797813	A1 19970207 <--
			US 1997-797816	A1 19970207 <--
			US 1997-797817	A1 19970207 <--
			US 1997-797820	A1 19970207 <--
			US 1996-17902P	P 19960329 <--
			WO 1997-US5128	A2 19970318 <--
			AU 1998-62756	A3 19980206 <--

EP 1999-117292 A3 19980206 <--  
 WO 1998-US2619 W 19980206 <--  
 AU 2000-72260 A3 20001214 <--  
 US 2000-746548 B1 20001219 <--  
 US 2001-1731 A1 20011031 <--  
 US 2003-395685 A3 20030324 <--


AB Carrier compds. and compns. which are useful in the delivery of active agents are provided. The carrier compound can be an amino acid derivative, and the active agent can be a peptide, mucopolysaccharide, carbohydrate, or lipid. Methods of administration, including oral administration, and preparation are provided as well. For example, an oral solution contained parathyroid hormone 100 µg, 4-[4-(phenoxyacetyl)aminophenyl]butyric acid (as carrier) 400 mg, and water 1L.

IT 209961-45-5 209961-83-1 209961-85-3  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino acid derivs. as carriers for oral delivery of biol. active agents)


RN 209961-45-5 CAPLUS  
 CN Benzenebutanoic acid, 4-[[1-(1-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



RN 209961-83-1 CAPLUS  
 CN Benzenepropanoic acid, 4-[[3-(3-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



RN 209961-85-3 CAPLUS  
 CN Benzenepropanoic acid, 4-[[3-(3-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:457247 CAPLUS  
 DOCUMENT NUMBER: 129:113532

ORIGINAL REFERENCE NO.: 129:23203a,23206a  
 TITLE: Compounds and compositions for delivering active agents  
 INVENTOR(S): Leone-Bay, Andrea; Wang, Eric; Sarubbi, Donald J.; Leipold, Harry  
 PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA  
 SOURCE: U.S., 34 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 30  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5776888	A	19980707	US 1997-796338	19970207
CA 2279331	A1	19980813	CA 1998-2279331	19980206 <--
CA 2319672	A1	19980813	CA 1998-2319672	19980206 <--
CA 2319680	A1	19980813	CA 1998-2319680	19980206 <--
WO 9834632	A1	19980813	WO 1998-US2619	19980206 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862756	A	19980826	AU 1998-62756	19980206 <--
AU 738735	B2	20010927		
EP 993831	A2	20000419	EP 1999-117292	19980206 <--
EP 993831	A3	20010502		
EP 993831	B1	20080109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1015008	A1	20000705	EP 1998-905042	19980206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1093819	A2	20010425	EP 2000-122704	19980206 <--
EP 1093819	A3	20030514		
EP 1093819	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513080	T	20010828	JP 1998-535034	19980206 <--
NZ 337131	A	20010831	NZ 1998-337131	19980206 <--
AT 324907	T	20060615	AT 2000-122704	19980206 <--
PT 1093819	T	20060929	PT 2000-122704	19980206 <--
ES 2263428	T3	20061216	ES 2000-122704	19980206 <--
AT 383169	T	20080115	AT 1999-117292	19980206 <--
ES 2297909	T3	20080501	ES 1999-117292	19980206 <--
MX 9907290	A	20000531	MX 1999-7290	19990806 <--
NZ 507275	A	20011130	NZ 2000-507275	20001003 <--
NZ 507276	A	20020201	NZ 2000-507276	20001003 <--
JP 2001131090	A	20010515	JP 2000-311231	20001011 <--
JP 3964613	B2	20070822		
JP 2001139494	A	20010522	JP 2000-311230	20001011 <--
JP 4012679	B2	20071121		
AU 771024	B2	20040311	AU 2000-72261	20001214 <--
AU 771434	B2	20040325	AU 2000-72260	20001214 <--
HK 1037132	A1	20061103	HK 2001-107390	20011023 <--
AU 2004202745	A1	20040923	AU 2004-202745	20040623 <--
PRIORITY APPLN. INFO.:			US 1997-796334	A 19970207 <--

US 1997-796335	A 19970207 <--
US 1997-796336	A 19970207 <--
US 1997-796337	A 19970207 <--
US 1997-796338	A 19970207 <--
US 1997-796339	A 19970207 <--
US 1997-796340	A 19970207 <--
US 1997-796341	A 19970207 <--
US 1997-797100	A 19970207 <--
US 1997-797813	A 19970207 <--
US 1997-797816	A 19970207 <--
US 1997-797817	A 19970207 <--
US 1997-797820	A 19970207 <--
AU 1998-62756	A3 19980206 <--
CA 1998-2279331	A3 19980206 <--
EP 1998-905042	A3 19980206 <--
EP 1999-117292	A3 19980206 <--
JP 1998-535034	A3 19980206 <--
NZ 1998-337131	A1 19980206 <--
WO 1998-US2619	W 19980206 <--
AU 2000-72260	A3 20001214 <--

AB Carrier compds. and compns. which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well. Standard methods of preparation are mentioned for the 193 carrier compds.

listed, which primarily are N-(fatty acid) benzamide derivs. Examples are listed for the delivery of parathyroid hormone, recombinant human growth hormone, interferon and the evaluation of heparin in rats.


IT 209961-45-5P 209961-83-1P 209961-85-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide fatty acid derivs. for delivering active agents)


RN 209961-45-5 CAPLUS

CN Benzenebutanoic acid, 4-[[1-(hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)




RN 209961-83-1 CAPLUS

CN Benzenepropanoic acid, 4-[[3-(hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



RN 209961-85-3 CAPLUS

CN Benzenepropanoic acid, 4-[[3-(hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:430107 CAPLUS  
 DOCUMENT NUMBER: 129:113525  
 ORIGINAL REFERENCE NO.: 129:23203a,23206a  
 TITLE: Compounds and compositions for delivering active agents  
 INVENTOR(S): Leone-Bay, Andrea; Wang, Eric; Sarubbi, Donald J.; Leipold, Harry  
 PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA  
 SOURCE: U.S., 35 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 30  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5773647	A	19980630	US 1997-796337	19970207
CA 2279331	A1	19980813	CA 1998-2279331	19980206 <--
CA 2319672	A1	19980813	CA 1998-2319672	19980206 <--
CA 2319680	A1	19980813	CA 1998-2319680	19980206 <--
WO 9834632	A1	19980813	WO 1998-US2619	19980206 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862756	A	19980826	AU 1998-62756	19980206 <--
AU 738735	B2	20010927		
EP 993831	A2	20000419	EP 1999-117292	19980206 <--
EP 993831	A3	20010502		
EP 993831	B1	20080109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1015008	A1	20000705	EP 1998-905042	19980206 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1093819	A2	20010425	EP 2000-122704	19980206 <--
EP 1093819	A3	20030514		
EP 1093819	B1	20060503		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513080	T	20010828	JP 1998-535034	19980206 <--
NZ 337131	A	20010831	NZ 1998-337131	19980206 <--
AT 324907	T	20060615	AT 2000-122704	19980206 <--
PT 1093819	T	20060929	PT 2000-122704	19980206 <--
ES 2263428	T3	20061216	ES 2000-122704	19980206 <--

AT 383169	T	20080115	AT 1999-117292	19980206 <--
ES 2297909	T3	20080501	ES 1999-117292	19980206 <--
MX 9907290	A	20000531	MX 1999-7290	19990806 <--
NZ 507275	A	20011130	NZ 2000-507275	20001003 <--
NZ 507276	A	20020201	NZ 2000-507276	20001003 <--
JP 2001131090	A	20010515	JP 2000-311231	20001011 <--
JP 3964613	B2	20070822		
JP 2001139494	A	20010522	JP 2000-311230	20001011 <--
JP 4012679	B2	20071121		
AU 771024	B2	20040311	AU 2000-72261	20001214 <--
AU 771434	B2	20040325	AU 2000-72260	20001214 <--
HK 1037132	A1	20061103	HK 2001-107390	20011023 <--
AU 2004202745	A1	20040923	AU 2004-202745	20040623 <--

PRIORITY APPLN. INFO.:


US 1997-796334	A	19970207 <--
US 1997-796335	A	19970207 <--
US 1997-796336	A	19970207 <--
US 1997-796337	A	19970207 <--
US 1997-796338	A	19970207 <--
US 1997-796339	A	19970207 <--
US 1997-796340	A	19970207 <--
US 1997-796341	A	19970207 <--
US 1997-797100	A	19970207 <--
US 1997-797813	A	19970207 <--
US 1997-797816	A	19970207 <--
US 1997-797817	A	19970207 <--
US 1997-797820	A	19970207 <--
AU 1998-62756	A3	19980206 <--
CA 1998-2279331	A3	19980206 <--
EP 1998-905042	A3	19980206 <--
EP 1999-117292	A3	19980206 <--
JP 1998-535034	A3	19980206 <--
NZ 1998-337131	A1	19980206 <--
WO 1998-US2619	W	19980206 <--
AU 2000-72260	A3	20001214 <--

AB Carrier compds. and compns. therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well. Standard methods of preparation are mentioned for the 193 carrier compds. listed, which primarily are N-(fatty acid) benzamide derivs. Examples are listed for the delivery of parathyroid hormone, recombinant human growth hormone, interferon and the evaluation of heparin in rats.

IT 209961-45-5P 209961-83-1P 209961-85-3P  
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzamide fatty acids for delivering active agents)


RN 209961-45-5 CAPLUS

CN Benzenebutanoic acid, 4-[[[(1-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)




RN 209961-83-1 CAPLUS

CN Benzenebutanoic acid, 4-[[[(3-hydroxy-2-naphthalenyl)carbonyl]amino]- (CA INDEX NAME)



RN 209961-85-3 CAPLUS  
 CN Benzenepropanoic acid, 4-[[3-hydroxy-2-naphthalenyl]carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:527636 CAPLUS

DOCUMENT NUMBER: 127:152958

ORIGINAL REFERENCE NO.: 127:29485a,29488a

TITLE: Modified amino acid carriers, their preparation, and compositions containing them for delivering active agents

INVENTOR(S): Leone-Bay, Andrea; Paton, Duncan R.; Ho, Koc-Kan; DeMorin, Frenel

PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA

SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 231,622. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 30

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5643957	A	19970701	US 1994-335148	19941025 <--
US 5451410	A	19950919	US 1993-51019	19930422
US 5792451	A	19980811	US 1994-205511	19940302
US 5629020	A	19970513	US 1994-231622	19940422
CA 2203033	A1	19960502	CA 1995-2203033	19951016 <--
CA 2203033	C	20080729		
WO 9612473	A1	19960502	WO 1995-US13527	19951016 <--
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9539633	A	19960515	AU 1995-39633	19951016 <--
AU 711887	B2	19991021		
EP 783299	A1	19970716	EP 1995-937558	19951016 <--
EP 783299	B1	20030910		

	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE	
BR	9510168	A	19971014
HU	77759	A2	19980728
JP	10507762	T	19980728
JP	4223547	B2	20090212
AT	249422	T	20030915
ES	2207655	T3	20040601
US	5955503	A	19990921
US	6100298	A	20000808
NO	9701889	A	19970623
FI	9701776	A	19970425
US	20010003001	A1	20010607
AU	771024	B2	20040311
AU	771434	B2	20040325
US	20020120009	A1	20020829
US	6663887	B2	20031216
US	20040068013	A1	20040408
AU	2004202745	A1	20040923
BR	995-10168		19951016 <--
HU	1998-903		19951016 <--
JP	1996-514062		19951016 <--
AT	1995-937558		19951016 <--
ES	1995-937558		19951016 <--
US	1997-795833		19970206 <--
US	1997-795837		19970206 <--
NO	1997-1889		19970424 <--
FI	1997-1776		19970425 <--
US	2000-730156		20001205 <--
AU	2000-72261		20001214 <--
AU	2000-72260		20001214 <--
US	2002-90012		20020221 <--
US	2003-677906		20031001 <--
AU	2004-202745		20040623 <--
US	1993-51019	A2	19930422 <--
US	1994-205511	A2	19940302 <--
US	1994-231622	A2	19940422 <--
WO	1994-US4560	A2	19940422 <--
US	1994-335148	A	19941025 <--
WO	1995-US13527	W	19951016 <--
US	1997-795837	A1	19970206 <--
AU	1998-62756	A3	19980206 <--
US	1999-346970	A1	19990702 <--
US	2000-730156	A1	20001205 <--
AU	2000-72260	A3	20001214 <--
US	2002-90012	A1	20020221 <--

OTHER SOURCE(S): MARPAT 127:152958  
GI




I

AB Modified amino acid compds. useful in the delivery of active agents (peptides, carbohydrates, antigens, monoclonal antibodies, hormones, pesticides, etc.) are provided. Methods of administration and preparation are also provided. The effect of a composition containing e.g. interferon- $\alpha 2$  and e.g. I (preparation given) on the serum interferon level was determined

IT 177653-21-3 178558-97-9  
RL: AGR (Agricultural use); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(modified amino acid carrier preparation and compns. containing them for delivering active agents)


RN 177653-21-3 CAPLUS

CN Benzenebutanoic acid, 4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



RN 178558-97-9 CAPLUS

CN Benzenebutanoic acid, 4-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]-  
(CA INDEX NAME)



REFERENCE COUNT: 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L10 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:87 CAPLUS

DOCUMENT NUMBER: 126:31174

ORIGINAL REFERENCE NO.: 126:6341a,6344a

TITLE: Preparation of modified amino acid compounds for  
delivering active agents

INVENTOR(S): Leone-Bay, Andrea; Ho, Koc-Kan; Sarubbi, Donald J.;  
Milstein, Sam J.; Press, Jeffery Bruce

PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA; Leone-Bay, Andrea;  
Ho, Koc-Kan; Sarubbi, Donald, J.; Milstein, Sam, J.;  
Press, Jeffery, Bruce

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 30

PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9630036	A1	19961003	WO 1996-US4580	19960401 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 5650386	A	19970722	US 1995-414654	19950331
CA 2214323	A1	19961003	CA 1996-2214323	19960401 <--
CA 2214323	C	20080729		
AU 9656629	A	19961016	AU 1996-56629	19960401 <--
AU 712222	B2	19991104		
EP 817643	A1	19980114	EP 1996-913778	19960401 <--
EP 817643	B1	20070321		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9604880	A	19980519	BR 1996-4880	19960401 <--

HU 9901162	A2	19990830	HU 1999-1162	19960401 <--
HU 9901162	A3	20000728		
JP 2002506418	T	20020226	JP 1996-529751	19960401 <--
JP 3647041	B2	20050511		
RU 2203268	C2	20030427	RU 1997-118224	19960401 <--
JP 2003313157	A	20031106	JP 2003-140962	19960401 <--
PL 188523	B1	20050228	PL 1996-322494	19960401 <--
AT 357243	T	20070415	AT 1996-913778	19960401 <--
EP 1792624	A1	20070606	EP 2007-4042	19960401 <--
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, SI				
ES 2284168	T3	20071101	ES 1996-913778	19960401 <--
CZ 299295	B6	20080611	CZ 1997-3073	19960401 <--
US 5965121	A	19991012	US 1997-798023	19970206 <--
US 5989539	A	19991123	US 1997-798032	19970206 <--
US 6001347	A	19991214	US 1997-798031	19970206 <--
FI 9703828	A	19970929	FI 1997-3828	19970929 <--
NO 9704495	A	19971128	NO 1997-4495	19970929 <--
NO 325621	B1	20080630		
HK 1017995	A1	20050909	HK 1998-112664	19981202 <--
US 20010023240	A1	20010920	US 1999-305506	19990505 <--
US 6428780	B2	20020806		
US 6346242	B1	20020212	US 2000-499958	20000208 <--
AU 771024	B2	20040311	AU 2000-72261	20001214 <--
AU 771434	B2	20040325	AU 2000-72260	20001214 <--
US 20030045579	A1	20030306	US 2001-38426	20011019 <--
US 6623731	B2	20030923		
US 20030078302	A1	20030424	US 2002-142009	20020508 <--
US 6699467	B2	20040302		
US 20050101671	A1	20050512	US 2003-617266	20030709 <--
US 7067119	B2	20060627		
US 20040110839	A1	20040610	US 2003-623142	20030718 <--
US 6972300	B2	20051206		
AU 2004202745	A1	20040923	AU 2004-202745	20040623 <--
US 20050272815	A1	20051208	US 2005-172562	20050629 <--
JP 2007077170	A	20070329	JP 2006-335831	20061213 <--

PRIORITY APPLN. INFO.:

US 1995-414654	A2	19950331 <--
US 1995-3111P	P	19950901 <--
US 1996-17902P	P	19960329 <--
EP 1996-913778	A3	19960401 <--
JP 1996-529751	A3	19960401 <--
JP 2003-140962	A3	19960401 <--
WO 1996-US4580	W	19960401 <--
US 1997-798031	A1	19970206 <--
AU 1998-62756	A3	19980206 <--
US 1999-305506	A1	19990505 <--
US 2000-499958	A1	20000208 <--
AU 2000-72260	A3	20001214 <--
US 2001-38426	A1	20011019 <--
US 2002-142009	A1	20020508 <--
US 2003-617266	A1	20030709 <--

OTHER SOURCE(S): MARPAT 126:31174  
GI



AB Modified amino acid compds. [I (n = 0-3; m = 0-4; X = H, halo, OH, etc.), II (n = 0-3; X = 2-F, 3-MeO, 4-Me, etc.), etc.], useful in the delivery of active agents such as, e.g., human growth hormone, interferon, heparin, calcitonin, parathyroid hormone, were prepared. Thus, reaction of 8-aminocaproic acid with O-acetylsalicyloyl chloride in the presence of 2M aqueous NaOH afforded 57% III which was mixed with recombinant growth hormone (rhGH) in a phosphate buffer solution at pH 7-8 and administered orally to rats at 25 mg/kg of carrier and at 1 mg/kg of rhGH. The mean peak serum level of compound III was 60.92 ng/mL as compared to < 10 ng/mL for control.


IT 178558-97-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of modified amino acid compds. for delivering active agents)

RN 178558-97-9 CAPLUS

CN Benzenebutanoic acid, 4-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]-(CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:425385 CAPLUS

DOCUMENT NUMBER: 125:96071

ORIGINAL REFERENCE NO.: 125:17903a,17906a  
 TITLE: Modified amino acids as absorption enhancers for delivering active agents  
 INVENTOR(S): Leone-Bay, Andrea; Paton, Duncan R.; Ho, Kok-Kan; Demorin, Frenel  
 PATENT ASSIGNEE(S): Emisphere Technologies, Inc., USA  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 30  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9612473	A1	19960502	WO 1995-US13527	19951016 <--
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5643957	A	19970701	US 1994-335148	19941025 <--
CA 2203033	A1	19960502	CA 1995-2203033	19951016 <--
CA 2203033	C	20080729		
AU 9539633	A	19960515	AU 1995-39633	19951016 <--
AU 711887	B2	19991021		
EP 783299	A1	19970716	EP 1995-937558	19951016 <--
EP 783299	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9510168	A	19971014	BR 1995-10168	19951016 <--
JP 10507762	T	19980728	JP 1996-514062	19951016 <--
JP 4223547	B2	20090212		
AT 249422	T	20030915	AT 1995-937558	19951016 <--
NO 9701889	A	19970623	NO 1997-1889	19970424 <--
FI 9701776	A	19970425	FI 1997-1776	19970425 <--
AU 771024	B2	20040311	AU 2000-72261	20001214 <--
AU 771434	B2	20040325	AU 2000-72260	20001214 <--
AU 2004202745	A1	20040923	AU 2004-202745	20040623 <--

PRIORITY APPLN. INFO.:

US 1994-335148	A	19941025 <--
US 1993-51019	A2	19930422 <--
US 1994-205511	A2	19940302 <--
US 1994-231622	A2	19940422 <--
WO 1995-US13527	W	19951016 <--
AU 1998-62756	A3	19980206 <--
AU 2000-72260	A3	20001214 <--

AB Modified amino acid compds. as absorption enhancers are useful in the delivery of active agents. These compound are used as carriers to facilitate the delivery of a cargo to a target. Thus, 47.00 g acetylsalicyloyl chloride was added to a mixture of 50.00 g 4-(4-aminophenyl)butyric acid in 300 mL of 2M aqueous sodium hydroxide and the reaction was stirred at 25° for 2 h, then it was acidified with aqueous HCl to obtain a precipitate which was separated and washed to give 31.89 g 4-(2-hydroxyphenylcarbonylamino)p-phenylbutanoic acid (I). I was mixed with interferon  $\alpha$ -2 (II) in Tris-HCl buffer pH = 7-8 and was orally administered to rats at a rate of 300 mg I/kg and 1000  $\mu$ g II/kg. The mean peak serum level of II was 8213 as compared to 688 ng/mL for controls.


IT 177653-21-3P 178558-97-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(modified amino acids as absorption enhancers for delivering active agents)


RN 177653-21-3 CAPLUS

CN Benzenebutanoic acid, 4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



RN 178558-97-9 CAPLUS

CN Benzenebutanoic acid, 4-[[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:365477 CAPLUS

DOCUMENT NUMBER: 125:58518

ORIGINAL REFERENCE NO.: 125:11257a

TITLE: Heterocyclic naphthalene amides having leukotriene-antagonistic action

INVENTOR(S): Mauleon Casellas, David; Carganico, Germano; Fos Torro, Maria De Los Desampa; Garcia Perex, Maria Luisa; Palomer Benet, Albert

PATENT ASSIGNEE(S): Laboratorios Menarini S.A., Spain

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604267	A1	19960215	WO 1995-EP2970	19950727 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ				
RW: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ES 2103181	A1	19970816	ES 1994-1696	19940801
ES 2103181	B1	19980401		
AU 9532539	A	19960304	AU 1995-32539	19950727 <--
EP 775133	A1	19970528	EP 1995-929014	19950727 <--
EP 775133	B1	20010530		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
 ES 2156944 T3 20010801 ES 1995-929014 19950727 <--  
 PT 775133 T 20011030 PT 1995-929014 19950727 <--  
 GR 3036462 T3 20011130 GR 2001-401313 20010829 <--  
 PRIORITY APPLN. INFO.: ES 1994-1696 A 19940801 <--  
 WO 1995-EP2970 W 19950727 <--  
 OTHER SOURCE(S): MARPAT 125:58518  
 GI



I



II

AB Naphthalene amides I [chain containing A is bound to the 6- or 7-position of the 2-naphthol system; R1 = H or Me; R2 = H, F, Cl, or OMe, which is bound to the naphthalene system at any position except the 2- and the one occupied by the other substituent; R3 = H, F, Cl, or Br; A = CONR4 or NR4CO; R4 = H or Me; B = 5-tetrazolyl or CO2R5; R5 = H, Cl-4 alkyl, C<10 phenylalkyl; m = 0 or 1; n, p = 0-6; with the proviso that (n+p) ≤ 6] and their solvates and pharmaceutically acceptable salts have leukotriene-antagonistic action. The compds. are useful in the treatment of a variety of allergic and inflammatory conditions. For example, demethylation and Me esterification of 2-(6-methoxy-2-naphthyl)propionic acid (70%), followed by etherification with 2-(chloromethyl)quinoline (80%), saponification (99%), and amidation with

4-(1H-5-tetrazolyl)benzylamine-HCl

using EDC (65%), gave title compound II. In an assay for inhibition of LTD4-induced contraction of isolated guinea-pig ileum, II had IC50 of 13 nM. Prepns. of 33 compds. are given, plus results of two bioassays for selected compds.

IT 177735-77-2P 177735-83-0P 177735-85-2P


177735-87-4P 177735-90-9P 177735-93-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic naphthalene amides as leukotriene antagonists)


RN 177735-77-2 CAPLUS

CN Benzenebutanoic acid, 4-[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]-, methyl ester (CA INDEX NAME)




RN 177735-83-0 CAPLUS

CN Benzenecetic acid, 4-[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]-, methyl ester (CA INDEX NAME)



RN 177735-85-2 CAPLUS


CN Benzenecetic acid, 3-[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]-, methyl ester (CA INDEX NAME)



RN 177735-87-4 CAPLUS


CN Benzenebutanoic acid, 4-[[2-[6-[(7-chloro-2-quinolinyl)methoxy]-2-naphthalenyl]-1-oxopropyl]amino]-, methyl ester (CA INDEX NAME)

PAGE 1-A




Cl


RN 177735-90-9 CAPLUS  
 CN Benzenebutanoic acid, 4-[[[6-(2-quinolinylmethoxy)-2-naphthalenyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 177735-93-2 CAPLUS  
 CN Benzenebutanoic acid, 4-[[[7-(2-quinolinylmethoxy)-2-naphthalenyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



IT 177735-78-3P 177735-84-1P 177735-86-3P  
 177735-88-5P 177735-91-0P 177735-94-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic naphthalene amides as leukotriene antagonists)  
 RN 177735-78-3 CAPLUS  
 CN Benzenebutanoic acid, 4-[[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]- (CA INDEX NAME)




RN 177735-84-1 CAPLUS  
 CN Benzenebutanoic acid, 4-[[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]- (CA INDEX NAME)



RN 177735-86-3 CAPLUS


CN Benzenecetic acid, 3-[[1-oxo-2-[6-(2-quinolinylmethoxy)-2-naphthalenyl]propyl]amino]- (CA INDEX NAME)



RN 177735-88-5 CAPLUS

CN Benzenecetic acid, 4-[[2-[6-[(7-chloro-2-quinolinyl)methoxy]-2-naphthalenyl]-1-oxopropyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Cl

RN 177735-91-0 CAPLUS


CN Benzenecetic acid, 4-[[[6-(2-quinolinylmethoxy)-2-naphthalenyl]carbonyl]amino]- (CA INDEX NAME)



RN 177735-94-3 CAPLUS

CN Benzenecetic acid, 4-[[[7-(2-quinolinylmethoxy)-2-naphthalenyl]carbonyl]amino]- (CA INDEX NAME)

naphthalenyl]carbonyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:169303 CAPLUS

DOCUMENT NUMBER: 124:263652

ORIGINAL REFERENCE NO.: 124:48809a, 48812a

TITLE: Water-based black recording liquids containing azo dyes

INVENTOR(S): Sano, Hideo; Yamada, Masahiro; Nishimura, Tooru; Takimoto, Hiroshi

PATENT ASSIGNEE(S): Mitsubishi Kagaku KK, Japan

SOURCE: Jpn. Kokai Tokyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07331145	A	19951219	JP 1994-125100	19940607 <--
JP 3371542	B2	20030127		
PRIORITY APPLN. INFO.:			JP 1994-125100	19940607 <--
OTHER SOURCE(S):	MARPAT 124:263652			

GI



I



II

AB Title liqs., useful for ink-jet printing black inks, etc., contain aqueous medium and  $\geq 1$  I-type azo dye and  $\geq 1$  II-type azo dyes [as free acids; A, C = (substituted) Ph, (substituted) naphthyl; B, D = (substituted) phenylene, (substituted) naphthylene; R1-5 = H, C1-18 alkyl, C1-18 alkenyl, aryl, aralkyl, cycloalkyl, heterocycle; which may be


substituted;  $\geq 1$  R1-4 are carboxyl-substituted;  $n = 0-1$ . The liqs. may comprise water 35-93, water-soluble organic solvents 5-50, and the dyes 2-8%.

IT 175466-40-7

RL: TEM (Technical or engineered material use); USES (Uses)  
(black water-based jet printing inks containing disazo dyes)

RN 175466-40-7 CAPLUS

CN Benzenepropanoic acid, 4-[[7-[2-[4-[2-(3-fluorophenyl)diazanyl]-7-sulfo-1-naphthalenyl]diazanyl]-8-hydroxy-6-sulfo-2-naphthalenyl]amino]- (CA INDEX NAME)



L10 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:304927 CAPLUS

DOCUMENT NUMBER: 122:82085

ORIGINAL REFERENCE NO.: 122:15619a,15622a

TITLE: Preparation of acyclic peptides as cardiovascular agents (natriuretics).

INVENTOR(S): Voges, Klaus Peter; Henning, Rolf; Huebsch, Walter; Lenfers, Jan Bernd; Beuck, Martin; Theiss, Gudrun; Stasch, Johannes Peter; Hirth-Dietrich, Claudia

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 73 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4242946	A1	19940623	DE 1992-4242946	19921218
CA 2151961	A1	19940707	CA 1993-2151961	19931206 <--
WO 9414840	A1	19940707	WO 1993-EP3431	19931206 <--
W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN,				
MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				


AU 9456970 A 19940719 AU 1994-56970 19931206 <--  
 EP 674655 A1 19951004 EP 1994-902694 19931206 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
 PRIORITY APPLN. INFO.: DE 1992-4242946 A 19921218 <--  
 WO 1993-EP3431 W 19931206 <--  
 OTHER SOURCE(S): MARPAT 122:82085  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB R1COABDEGR2 [A = bond, Q1, Q2, Q3; a, b, d, f = 1,2; e = 0-2; R3, R10, R26  
 = H, alkyl, protecting group; R4, R5, R11, R12, R27, R28 = H, Me, etc.;  
 R4R5, R11R12 = atoms to form a 5-6 membered carbocycle; B = Q4, Q5, Q6,  
 etc.; j = 0-4; g = 1-3; R9 = H, protecting group; D, E, G = B, Q7; R1 =  
 alkyl, pyridyl, quinolyl, etc.; R2 = Q8; k, l = 0-2; R29, R30 = H,  
 protecting group, (substituted) alkyl], were prepared as natriuretics (no  
 data). Thus, title compound (I) was prepared on Tentagel-S-NH2 resin using  
 Fmoc-protected amino acids.  
 IT 160346-05-4P 160346-06-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as intermediate for acyclic peptide cardiovascular agent)  
 RN 160346-05-4 CAPLUS  
 CN Benzeneacetic acid, 4-[(2-naphthalenylcarbonyl)amino]-, ethyl ester (CA  
 INDEX NAME)



RN 160346-06-5 CAPLUS  
 CN Benzeneacetic acid, 4-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)




L10 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1994:298479 CAPLUS  
 DOCUMENT NUMBER: 120:298479  
 ORIGINAL REFERENCE NO.: 120:52601a, 52604a  
 TITLE: Pyridyl-derivative thromboxane antagonists  
 INVENTOR(S): Soyka, Rainer; Eisert, Wolfgang; Mueller, Thomas;  
 Weisenberger, Johannes  
 PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany  
 SOURCE: U.S., 19 pp. Cont.-in-part of U.S. Ser. No. 796,525,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5286736	A	19940215	US 1993-5725	19930119 <--
DE 4037112	A1	19920527	DE 1990-4037112	19901122

PRIORITY APPLN. INFO.:  
DE 1990-4037112 A 19901122 <--  
US 1991-796525 B2 19911122 <--

OTHER SOURCE(S): MARPAT 120:298479  
GI




AB The title compds. (I; A = direct bond, C3-4 cycloalkylene, C3-4 cycloalkylidene, (un)substituted C2-3 alkylene, OCH2CH2, etc.; R1 = (un)substituted C1-4 alkyl, C5-7 cycloalkyl, Ph; R2 = H, C1-4 alkyl; R3 = pyridyl; R4, R5 = H, or together may represent a C-C bond; R6 = HO, C1-3 alkoxy; X = CO, CS; n = 2-4), useful as thromboxane antagonists, antiallergic agents (no data), etc., are prepared and I-containing formulations presented. Thus, 6-[4-(4-methylbenzenesulfonylamino)phenyl]-6-(3-pyridyl)-5-hexenoic acid was prepared in 53% yield by the condensation of 4-methylbenzenesulfonyl chloride with Me 6-(4-aminophenyl)-6-(3-pyridyl)-5-hexenoate followed by saponification.

IT 142669-03-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as thromboxane antagonist)

RN 142669-03-2 CAPLUS

CN 5-Hexenoic acid, 6-[3-[(2-naphthalenylcarbonyl)amino]phenyl]-6-(3-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1993:147306 CAPLUS  
DOCUMENT NUMBER: 118:147306  
ORIGINAL REFERENCE NO.: 118:25323a, 25326a  
TITLE: Preparation of  $\alpha$ -oxobenzeneacetic acids and related compounds as antiischemics and antiarrhythmics  
INVENTOR(S): Guthrie, Robert William; Heathers, Guy Phillip; Higgins, Alan John; Kachensky, David Francis; Kierstead, Richard Wightmann; LeMahieu, Ronald Andrew; Mullin, John Guilfoyle, Jr.; Tilley, Jefferson Wright  
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., AG, Switz.  
SOURCE: Eur. Pat. Appl., 166 pp.

DOCUMENT TYPE: CODEN: EPXXDW  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 2 English  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 512352	A2	19921111	EP 1992-107135	19920427 <--
EP 512352	A3	19930310		
EP 512352	B1	19960327		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE  
 US 5344843 A 19940906 US 1992-850620 19920313 <--  
 PRIORITY APPLN. INFO.: US 1991-698014 A 19910509 <--  
 US 1992-850620 A 19920313 <--

OTHER SOURCE(S): MARPAT 118:147306  
 GI




AB Title compds. I [R1 = OH, OR3, NR4R5; 1 of R4, R5 = H, C1-7 (hydroxy)alkyl and the other = H, OH, C1-7 alkyl, C1-7 alkoxy; R3 = (CH2CH2O)mH, CH2CHOHCH2OH, 2,2-dimethyl-1,3-dioxolan-4-yl, CH2CH2NH2, etc.; m = 1-4; R2, R2' = H, C1-7 alkyl, aryl-C1-7 alkyl, C1-7 alkoxy, OH, NH2, C1-7 alkylamino, cyano, halo, SH, etc.; A = bond, O, NR7, S, SO, SO2, C.tplbond.C, CH:CH, CH2CH, NR8CO, CONR9; R7 = H, C1-7 alkyl, acyl; R8,R9 = H, C1-7 alkyl; n = 0-10; B = bond, groups defined for A, CO, CS, (OCH2CH2)mO, etc.; Z = O, S, CR2:CR2', N:CR2, CR2:N, NR11; R11 = H, C1-7 alkyl; XY = O, S, :NOH, alkoxyimino, alkenyloxyimino, hydrazono, etc., or individually 1 of X and Y = halo and the other = H, halo, C1-7 alkyl, aryl-C1-7 alkyl; other possibilities for X and Y; Q = cycloalkyl, aryl, heterocyclyl; with provisos] were prepared as drugs to prevent injury to ischemic tissue and arrhythmias during and after a myocardial infarction. Thus, Me 4-hydroxy- $\alpha$ -oxobenzeneacetate in DMF containing NaH was O-alkylated by Ph(CH2)3Br and the resultant product was hydrolyzed by NaOH in MeOH to give title compound II. II had IC50 of 0.5  $\mu$ M against carnitine acyltransferase 1 in mitochondria. Over 200 I were prepared

IT Capsules containing I were also prepared  
 145796-37-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as antiischemic and antiarrhythmic)

RN 145796-37-8 CAPLUS

CN Benzeneacetic acid, 4-[[2-(2-naphthalenyl)ethyl]amino]- $\alpha$ -oxo- (CA  
 INDEX NAME)



L10 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:633858 CAPLUS

DOCUMENT NUMBER: 117:233858

ORIGINAL REFERENCE NO.: 117:40439a, 40442a

TITLE: Preparation of  
 o-pyridyl-o-[(acylamino)phenyl]alkenoates  
 as thromboxane antagonists and biosynthesis inhibitors  
 Soyka, Rainer; Eisert, Wolfgang; Mueller, Thomas;  
 Weisenberger, Johannes

INVENTOR(S): Thomae, Dr. Karl, G.m.b.H., Germany

PATENT ASSIGNEE(S): Eur. Pat. Appl., 46 pp.

SOURCE: CODEN: EPXXDW

DOCUMENT TYPE: Patent



LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 487095	A1	19920527	EP 1991-119889	19911121 <--
EP 487095	B1	19960228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 4037112	A1	19920527	DE 1990-4037112	19901122
AU 9187964	A	19920528	AU 1991-87964	19911119 <--
AU 640063	B2	19930812		
IL 100097	A	19950731	IL 1991-100097	19911120 <--
CA 2055950	A1	19920523	CA 1991-2055950	19911121 <--
FI 9105484	A	19920523	FI 1991-5484	19911121 <--
NO 9104567	A	19920525	NO 1991-4567	19911121 <--
NO 175634	B	19940801		
NO 175634	C	19941109		
HU 60472	A2	19920928	HU 1991-3644	19911121 <--
HU 213676	B	19970929		
JP 04275273	A	19920930	JP 1991-305990	19911121 <--
ZA 9109205	A	19930521	ZA 1991-9205	19911121 <--
RU 2028292	C1	19950209	RU 1991-5010111	19911121 <--
AT 134619	T	19960315	AT 1991-119889	19911121 <--
ES 2084756	T3	19960516	ES 1991-119889	19911121 <--
PRIORITY APPLN. INFO.: DE 1990-4037112 A 19901122 <--				

GI



AB Title compds. [I; n = 2-4; X = CO, CS, SO2; R1 = (phenyl)alkyl, cycloalkyl, naphthyl, biphenyl, indolyl, thienyl, (substituted) Ph, etc.,


R2 = H, alkyl; R3 = pyridyl; R4, R5 = H; R4, R5 = bond; R6 = OH, alkoxy; A = bond, alkylene, cycloalkylene, cycloalkylidene, oxyalkylene, etc.), were prepared Thus, Me 6-(4-aminophenyl)-6-(3-pyridyl)hex-5-enoate (preparation starting from nicotinoyl chloride hydrochloride and N-acetylaniline given) was stirred with 4-MeC6H4COCl and Et3N in CH2Cl2 to give the sulfonamide, which was heated with 10 N NaOH in EtOH at 50° to give title compound II. I inhibited human thromboxane synthetase with IC50 = 0.004-0.090 μM. Various dosage forms were prepared containing (-)-5E-6-[4-(Z-2-(4-chlorophenyl)cyclopropyl-1-carboxamido)phenyl]-6-(3-pyridyl)hex-5-enoic acid.

IT 142669-03-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as thromboxane antagonist and synthesis inhibitor)

RN 142669-03-2 CAPLUS

CN 5-Hexenoic acid, 6-[3-[(2-naphthalenylcarbonyl)amino]phenyl]-6-(3-pyridinyl)- (CA INDEX NAME)



L10 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1981:183366 CAPLUS

DOCUMENT NUMBER: 94:183366

ORIGINAL REFERENCE NO.: 94:29883a,29886a

TITLE: Hydrophilic color coupler composition containing diepoxide

INVENTOR(S): Viro, Felix; Emmi, Salvatore

PATENT ASSIGNEE(S): GAF Corp., USA

SOURCE: U.S., 4 pp. Cont.-in-part of U.S. 3,989,529.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4252894	A	19810224	US 1975-624923	19751022 <--
US 3989529	A	19761102	US 1974-518798	19741029
CA 1061155	A1	19790828	CA 1975-233859	19750821 <--
BE 833601	A1	19760319	BE 1975-160186	19750919 <--
JP 51067132	A	19760610	JP 1975-130282	19751029 <--
BE 846714	A1	19770329	BE 1976-171050	19760929 <--
FR 2328987	A1	19770520	FR 1976-29790	19761004 <--
FR 2328987	B1	19790112		
JP 52051938	A	19770426	JP 1976-125579	19761021 <--
DE 2647487	A1	19770428	DE 1976-2647487	19761021 <--
PRIORITY APPLN. INFO.:			US 1974-518798	A2 19741029 <--
			US 1975-624923	A 19751022 <--

GI For diagram(s), see printed CA Issue.

AB Hydrophilic coupler-oil solns. are stabilized by the addition of ethylene glycol diglycidyl ether or a diepoxide (low mol weight polymer, 170-400 mol weight). Thus, coupler I 5 g was dissolved in a solution containing di-Bu phthalate

4, MeOH 3, and Eponite 100 4 mL, dispersed in an aqueous solution of gelatin 1

mL, in H<sub>2</sub>O 45 and Alkanol B (10% aqueous solution Na alkylnaphthalenesulfonate) 3  
 and added with mixing to a Ag (I,Br) emulsion 100 g to give a coatable  
 photog. emulsion.  
 IT 28341-83-5  
 RL: USES (Uses)  
 (stabilization of di-Bu phthalate solution containing, diepoxide in, for  
 dispersion in photog. emulsion)  
 RN 28341-83-5 CAPLUS  
 CN Benzenepropanoic acid, 3-[[[(1-hydroxy-4-sulfo-2-  
 naphthalenyl)carbonyl]amino]-4-(methyltetradecylamino)- (CA INDEX NAME)




L10 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1977:484684 CAPLUS  
 DOCUMENT NUMBER: 87:84684  
 ORIGINAL REFERENCE NO.: 87:13455a,13458a  
 TITLE: 3-Substituted aminophenylacetic acid derivatives  
 Kobayashi, Toshihiko; Hiranuma, Hidetoshi; Onoya,  
 Masatoshi  
 INVENTOR(S): Mitsubishi Yuka Yakuhin Co., Ltd., Japan  
 PATENT ASSIGNEE(S): Jpn. Kokai Tokkyo Koho, 13 pp.  
 SOURCE: CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51149240	A	19761222	JP 1975-72635	19750617 <--
PRIORITY APPLN. INFO.:			JP 1975-72635	A 19750617 <--

GI



AB Title acids I (R = includes MeCOCH<sub>2</sub>CO, substituted benzoyl, 4-MeC<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>,  
 $\alpha$ -naphthyl, cinnamoyl, PhNHCO; R<sub>1</sub> = Me, allyl, HC.tplbond.CCH<sub>2</sub>),  
 their alkyl esters, and salts were prepared by acylation, ureidation, or

sulfonylation of 3-aminophenylacetic acid derivs. I (R = H), their alkyl esters, or salts. I had antiinflammatory activity (data given in carrageenin edema tests in rats). Thus, reduction of 3,4-O2N(MeO)C6H3CH2CO2H gave 3,4-H2N(MeO)C6H3CH2CO2H, which was stirred with (EtCO)2O to precipitate

77%


I (R = EtCO, R1 = Me). Among 47 addnl. I prepared were (R, R1 given): HO2C(CH2)3Me; 4-ClC6H4OCH2CHMe; 3,4-Cl(CH2:CHCH2O)C6H4CH2COMe, and cyclohexylcarbonyl Me.

IT 63305-22-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and antiinflammatory activity of)

RN 63305-22-6 CAPLUS

CN Benzeneacetic acid, 4-methoxy-3-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



L10 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1977:460757 CAPLUS

DOCUMENT NUMBER: 87:60757

ORIGINAL REFERENCE NO.: 87:9569a,9572a

TITLE: Dispersing hydrophilic color coupler

INVENTOR(S): Viro, Felix; Emmi, Salvatore

PATENT ASSIGNEE(S): GAF Corp., USA

SOURCE: Ger. Offen., 18 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2647487	A1	19770428	DE 1976-2647487	19761021 <--
US 4252894	A	19810224	US 1975-624923	19751022 <--
PRIORITY APPLN. INFO.:			US 1975-624923	A 19751022 <--
			US 1974-518798	A2 19741029 <--

GI



I

AB A method for dispersing hydrophilic color couplers in aqueous gelatin Ag

halide emulsions using an epoxide compound is described. Thus, 4 g coupler I was dissolved in a warm solution containing 3 mL dibutyl phthalate, 3 mL Eponite 100 (II) and 3 mL MeOH. After cooling the solution remained clear. I precipitated upon cooling from a similar solution not containing II.


IT 28341-83-5

RL: USES (Uses)

(dispersing of color coupler of, in photog. silver halide emulsions, epoxide compds. for)

RN 28341-83-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[1-hydroxy-4-sulfo-2-naphthalenyl]carbonyl]amino]-4-(methyltetradecylamino)- (CA INDEX NAME)



L10 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1970:436606 CAPLUS

DOCUMENT NUMBER: 73:36606

ORIGINAL REFERENCE NO.: 73:6055a,6058a

TITLE: 1-Hydroxy-2-naphthanilides as photographic color couplers

INVENTOR(S): Altavilla, Alex P.; Hoffstadt, Walter F.; Rauch, Emil

PATENT ASSIGNEE(S): GAF Corp.

SOURCE: Ger. Offen., 41 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1939301	A	19700212	DE 1969-1939301	19690801 <--
US 3622337	A	19711123	US 1968-749650	19680802
FR 2016852	A5	19700515	FR 1969-25255	19690724 <--
FR 2016852	B1	19741004		
GB 1282486	A	19720719	GB 1969-1282486	19690729 <--
ES 370111	A1	19710801	ES 1969-370111	19690731 <--
BE 736937	A	19700116	BE 1969-736937	19690801 <--
			US 1968-749650	A 19680802 <--

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.

AB I are prepared 4,3-Cl(O2N)C6H3CH:CHCO2H was condensed with MeNHC14H29, reduced (Na2S2O4), condensed with 1,2-HOC10H6CO2Ph, and hydrogenated (PtO2) to give I [R = R2 = H, R1 = NMeC14H29(Q), R3 = CH2CH2CO2H(Q1)]. Also prepared were I (R-R3 given): SO3H, Q, H, Q1; Br, Q, H, CH2CHBrCO2H; H, H, Q, Q1; H, C14H29O, H, CH2CH(CO2H)C6H4CO2H-4; H, C15H31, OCH2CO2H, H; H, H, O(CH2)nCON(C18H37)C6H3(CO2H)2-3,5 (Q2, n = 3), H; H, Q2(n = 1), H, H; H, Q2(n = 1), H; H, C14H29O, H, Q1.

IT 28341-47-1P 28341-62-0P 28341-80-2P


28341-82-4P 28341-83-5P 28341-84-6P

28341-85-7P 28382-81-2P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(preparation of)


RN 28341-47-1 CAPLUS

CN Benzenepropanoic acid, 4-carboxy- $\alpha$ -[[3-[[[(1-hydroxy-2-naphthalenyl)carbonyl]amino]-4-(tetradecyloxy)phenyl]methylene]- (CA INDEX NAME)




RN 28341-62-0 CAPLUS

CN Benzenepropanoic acid, 3-[[[(1-hydroxy-2-naphthalenyl)carbonyl]amino]-4-(tetradecyloxy)- (CA INDEX NAME)




RN 28341-80-2 CAPLUS

CN Benzenepropanoic acid, 3-[[[(1-hydroxy-2-naphthalenyl)carbonyl]amino]-4-(methyltetradecylamino)- (CA INDEX NAME)




RN 28341-82-4 CAPLUS

CN 2-Propenoic acid, 3-[3-[[[(1-hydroxy-2-naphthalenyl)carbonyl]amino]-4-(methyltetradecylamino)phenyl]- (CA INDEX NAME)




RN 28341-83-5 CAPLUS

CN Benzenepropanoic acid, 3-[[[1-hydroxy-4-sulfo-2-naphthalenyl]carbonyl]amino]-4-(methyltetradecylamino)- (CA INDEX NAME)




RN 28341-84-6 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -bromo-3-[[[4-bromo-1-hydroxy-2-naphthalenyl]carbonyl]amino]-4-(methyltetradecylamino)- (CA INDEX NAME)




RN 28341-85-7 CAPLUS

CN Benzenepropanoic acid, 5-[[[1-hydroxy-2-naphthalenyl]carbonyl]amino]-2-(methyltetradecylamino)- (CA INDEX NAME)




RN 28382-81-2 CAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -(4-carboxyphenyl)-3-[[1-(1-hydroxy-2-naphthalenyl)carbonyl]amino]-4-(tetradecyloxy)- (CA INDEX NAME)



L10 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1964:447706 CAPLUS  
 DOCUMENT NUMBER: 61:47706  
 ORIGINAL REFERENCE NO.: 61:8250h,8251a  
 TITLE: Derivatives of 2-arylamino-1,4-naphthoquinone  
 INVENTOR(S): Vinograd, L. Kh.  
 SOURCE From: Byul. Izobret. i Tovar-nykh Znakov 1964(9), 27..  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	SU 162156		19640416	SU	19630611 <--
PRIORITY APPLN. INFO.:				SU	19630611 <--
AB	The title compds. are prepared by the reaction of 1,4-dihydroxynaphthalene (I) with aromatic nitroso compds. E.g., 1.6 g. I in 10 ml. EtOH boiled 1 hr. with 1.23 g. nitrosophenol in 12 ml. EtOH yields 94% 2-(4-hydroxyphenylamino)-1,4-naph-thoquinone, m. 256-8° (EtOH).				
IT	95426-03-2P, Hydrocinnamic acid, p-[(1,4-dihydro-1,4-dioxo-2-naphthyl)amino]-, methyl ester RL: PREP (Preparation)				
RN	95426-03-2 CAPLUS				
CN	Benzenepropanoic acid, 4-[(1,4-dihydro-1,4-dioxo-2-naphthalenyl)amino]-, methyl ester (CA INDEX NAME)				



L10 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1964:447705 CAPLUS  
 DOCUMENT NUMBER: 61:47705  
 ORIGINAL REFERENCE NO.: 61:8250e-h  
 TITLE: 1-[3-Chloro-4-(2-diethylaminoethoxy)phenyl] indan  
 INVENTOR(S): Huebner, Charles F.; Bencze, William L.

PATENT ASSIGNEE(S): CIBA Ltd.  
 SOURCE: 19 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	FR M2350		19640323	FR	<--
				US	<--


PRIORITY APPLN. INFO.:  
 GI For diagram(s), see printed CA Issue.  
 AB The title compound (I) is a fungicide effective against dermatophytes. I was active in vitro against Trichophyton mentagrophytes, T. interdigitale, T. gallinae, Microsporum audouini, M. canis, M. gypseum, and Sporotrichum schenkkii. Solns., suspensions, emulsions, creams, or ointments containing 1-2% I or its salts were described for topical application. A 3% cream caused skin irritation for the guinea pig but not for humans. To 4.6 g. Na in 200 ml. EtOH was added 42 g. 1-(4hydroxyphenyl)indan (II), the mixture refluxed 2 hrs., and the solvent evaporated to give the Na salt (III) of II. III was dissolved in 150 ml. CS2 and 1 mole Cl was dissolved in the solution. After the reaction subsided, the inorg. precipitate was filtered off, the CS2 evaporated, the residue diluted with H2O and extracted with Et2O.

Distillation gave  
 1(3-chloro-4-hydroxyphenyl)indan (IV), b0.5 160-3° and a little  
 1-(3,5-dichloro-4-hydroxyphenyl)indan, b0.5 175°. A solution of 7 g.  
 IV in xylene was added dropwise to 1.67 g. NaH in 50 ml. xylene, the mixture refluxed 3 hrs., 3.8 g. 1-chloro-2-diethylaminoethane in xylene added and refluxing continued overnight. The solution was cooled, acidified with 15% HCl, NH4OH added, the aqueous phase extracted with Et2O, and the Et2O, dried  
 with  
 MgSO4 and evaporated The residue was treated with HCl MeOH to give I.HCl, m. 147-9°.

IT 95426-03-2P, Hydrocinnamic acid,  
 p-[(1,4-dihydro-1,4-dioxo-2-naphthyl)amino]-, methyl ester  
 RL: PREP (Preparation)  
 (preparation of)

RN 95426-03-2 CAPLUS

CN Benzenepropanoic acid, 4-[(1,4-dihydro-1,4-dioxo-2-naphthalenyl)amino]-, methyl ester (CA INDEX NAME)



=> fil stnguide  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
221.22	415.00

SINCE FILE ENTRY	TOTAL SESSION
-29.52	-29.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
 CA SUBSCRIBER PRICE

FILE 'STINGUIDE' ENTERED AT 09:07:42 ON 18 FEB 2009  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Feb 13, 2009 (20090213/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

1.26 416.26

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

0.00 -29.52

STN INTERNATIONAL LOGOFF AT 09:18:41 ON 18 FEB 2009